

(19)

Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

**EP 1 188 446 A1**

(12)

**EUROPEAN PATENT APPLICATION**

(43) Date of publication:  
20.03.2002 Bulletin 2002/12

(21) Application number: 00402562.3

(22) Date of filing: 15.09.2000

(51) Int Cl.7: **A61K 39/385**, A61K 47/48,  
A61K 39/00, A61P 29/00,  
A61P 31/00, A61P 33/00,  
A61P 35/00

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE**  
Designated Extension States:  
**AL LT LV MK RO SI**

(71) Applicants:  
• **INSTITUT PASTEUR**  
75724 Paris Cédex 15 (FR)  
• **CENTRE NATIONAL DE  
LA RECHERCHE SCIENTIFIQUE**  
75016 Paris Cédex (FR)

(72) Inventors:  
• **Leclerc, Claude**  
75015 Paris (FR)

• **Guermonprez, Pierre**  
94280 Cachan (FR)  
• **Ladant, Daniel**  
94230 Cachan (FR)  
• **Guiso, Nicole**  
75008 Paris (FR)  
• **Khelef, Nadia**  
75002 Paris (FR)

(74) Representative: **Desaix, Anne et al**  
**Ernest Gutmann - Yves Plasseraud S.A.**  
3, rue Chauveau-Lagarde  
75008 Paris (FR)

(54) **Proteinaceous vectors for molecule delivery to CD11b expressing cells**

(57) The invention relates to a novel use of a *Bordetella* adenylcyclase toxin in the manufacturing of vectors for targeting *in vivo* a molecule of interest, specifically to CD11b expressing cells. The invention also relates to an immunogenic composition that primes im-

mune responses to pharmaceutical compositions and to a new proteinaceous vector for molecule delivery to CD11b expressing cells.

**EP 1 188 446 A1**

**BEST AVAILABLE COPY**

## Description

### BACKGROUND OF THE INVENTION

[0001] The invention relates to a novel use of a *Bordetella* adenylcyclase toxin in the manufacturing of vectors for targeting *in vivo* a molecule of interest, specifically to CD11b expressing cells. The invention also relates to an immunogenic composition that primes immune responses to pharmaceutical compositions and to a new proteinaceous vector for molecule delivery to CD11b expressing cells.

[0002] *Bordetella pertussis*, the causative agent of whooping cough, secretes several toxins including the well-known pertussis toxin (PT) and the adenylate cyclase toxin (CyaA) or also adenylcyclase. CyaA is a critical virulence factor of *B. pertussis* in the murine respiratory model that is required for the early steps of lung colonization. Indeed, genetic deletion of this toxin dramatically decreases the pathological effects of *B. pertussis* infection, reducing the number of bacteria recovered from the lung and almost abolishing the inflammatory cell recruitment and the lung lesions observed after infection [Weiss et al., 1984; Weiss et al., 1989; Gross et al., 1992; Khelef et al., 1992; Khelef et al., 1994; Gueirard et al., 1998]. Moreover, CyaA is an antigen protective against *B. pertussis* infection in the murine respiratory model [Guiso et al., 1989; Guiso et al., 1991].

[0003] Originally discovered by Hewlett et al in *B. pertussis* culture supernatants [Hewlett et al., 1976], the adenylate cyclase was later found to be activated by the eukaryotic calmodulin [Wolff et al., 1980]. This striking feature quickly found a rationale when it was shown by Confer and Eaton that the adenylate cyclase could enter into eukaryotic cells where, upon activation by calmodulin, it could trigger a large increase in cAMP within these target cells [Confer et al., 1982].

[0004] Adenylate cyclase is encoded by the *cyaA* gene, and its expression, like that of other virulence genes of *B. pertussis*, is coordinately regulated by environmental signals. The *cyaA* gene is part of an operon that also contains genes *cya B*, *D* and *E*, that are required for CyaA secretion [Ladant et al., 1999].

[0005] The CyaA toxin is a bifunctional protein of 1706 residues that is made of a N-terminal catalytic domain of 400 amino acids and a C-terminal part of 1306 residues which is responsible for the binding of the toxin to target cell membrane and the subsequent delivery of the catalytic moiety into the cell cytosol [Sakamoto et al., 1992] [Ladant et al., 1999]. This part also exhibits a weak hemolytic activity due to its ability to form cation-selective channels in biological membranes [Benz et al., 1994] [Gray et al., 1998]. This region is homologous to *Escherichia coli* hemolysin and other members of the RTX (Repeat in ToXin) family of bacterial toxins. In particular, it contains a series of glycine and aspartate-rich nonapeptide repeats that are involved in calcium binding [Rose et al., 1995] [Coote et al., 1992].

[0006] The CyaA polypeptide is synthesized as an inactive protoxin that is converted to an active toxin by posttranslational palmitoylation of two internal lysines (lysines 856 and 963). This modification requires the product of an accessory gene, *cyaC*, which is located nearby *cyaA* on *B. pertussis* chromosome.

[0007] CyaA has been shown to bind to and invade a variety of cell types including cells lacking membrane traffic like mammalian erythrocytes [Rogel et al., 1992]. This suggested that the catalytic domain of CyaA is directly translocated across the plasma membrane of target cells. The internalization of the catalytic domain into the cell cytosol is calcium and temperature-dependent and depends upon the plasma membrane potential [Rogel et al., 1992] [Karimova et al., 1998] [Otero et al., 1995]. However, the molecular mechanisms by which the toxin transports its N-terminus catalytic domain across the membrane remain largely unknown to date. Furthermore no specific receptor has been reported for CyaA binding.

[0008] The physiological consequences of cellular intoxication by CyaA were characterized *in vitro* in phagocytes. Confer and Eaton first showed that the AC extracted from *B. pertussis* increases the intracellular cAMP level in neutrophils or macrophages leading to an inhibition of chemotaxis and bactericidal functions such as superoxide generation and phagocytic abilities [Confer et al., 1982]. These activities were later confirmed with purified toxins or with bacterial mutants genetically deleted of CyaA [Pearson et al., 1987; Friedman et al., 1987] [Njamkepo et al., 2000]. On the contrary, and despite significant changes in their cAMP content, the viability of cell lines from non-hematopoietic origin appeared to be unaffected by the CyaA intoxication [Bassiniet et al., 2000]. Moreover, the present inventors previously demonstrated that *B. pertussis* CyaA can trigger macrophage apoptosis *in vitro* [Khelef et al., 1993; Khelef et al., 1995] and *in vivo* [Gueirard et al., 1998]. In these models, genetic deletion of CyaA abolished macrophage apoptosis, but not neutrophil death, suggesting that CyaA i) is mainly responsible for macrophage apoptosis, ii) might be responsible for neutrophil apoptosis, but that another factor may also be responsible. Besides that, *in vivo* studies performed in a murine model of *B. bronchiseptica* infection (the animal homologue of *B. pertussis* whose CyaA is closely related) demonstrates that the major target of *B. bronchiseptica* CyaA toxicity is a GM-CSF-dependent and cyclophosphamide-sensitive population that controls the early steps of infection [Harvill et al., 1999]. These criterions identified neutrophils and possibly other cells including macrophages or dendritic cells. These populations of target cells for CyaA is the same that limits the early phases of infection and favors the development of an adaptive immune response that controls the latter phases of infection [Harvill et al., 1999].

[0009] Unlike other toxins, CyaA has been considered for a long time, as independent of any receptor binding.

This is based on the observations that i) CyaA can intoxicate a wide variety of model cell lines from various origin [Ladant et al., 1999] ii) CyaA binds to Jurkat cells and sheep erythrocytes in a non saturable fashion [Gray et al., 1999]. However, some specificity has been found in respect of cells infected by CyaA. Indeed, *in vivo* studies showed that during murine respiratory infection with *Bordetella* species, CyaA destroyed specifically leukocytes (especially macrophages) without damaging dramatically epithelial cells [Gueirard et al., 1998; Harvill et al., 1999].

[0010] It has been proposed in patent application WO 93/21324 to use the recombinant *Bordetella* adenylcyclase to induce a CD4<sup>+</sup> T cell or a CD8<sup>+</sup> T cell response; however, since no specific receptor for *Bordetella* adenylcyclase was identified, it was not known if the antigen presentation was related to uptake by non professional antigen presenting cell followed by cross-priming and presentation by dendritic cells or if the antigen was targeted to professional Antigen Presenting Cells (pAPC). [0011] In line with their surface phenotype APC and more specifically, dendritic cells (high expression of MHC I and II, costimulatory and adhesion molecules) represent the most potent APC in many *in vitro* assay for the priming of naive T cells [Bell et al., 1999; Viola et al., 1999]. Other APC like resting naive B cells, for example, could even be tolerogenic since injection of resting, male B cells into female hosts leads to the specific tolerization of male-specific CD8<sup>+</sup> T cells [Fuchs et al., 1992]. *In vitro*, naive B cells could delete naive CD8<sup>+</sup> T cells via a Fas dependent-mechanism [Bennett et al., 1998].

[0012] Moreover, Ag presentation by dendritic cells correlates *in vivo* with the induction of T cell responses. This has been established for MHCII-restricted Ag presentation. Adjuvant-free Ag injection via the intravenous (iv) route usually does not induce T cell priming [Kyburz et al., 1993; Aichele et al., 1994; Aichele et al., 1995] and leads to Ag presentation by non-specific B cells [Guery et al., 1997] [Zhong et al., 1997; Reis e Sousa et al., 1999] and, eventually dendritic cells [Crowley et al., 1990] [Zhong et al., 1997; Reis e Sousa et al., 1999]. In contrast, local immunization strategies like subcutaneous (sb) immunization in the presence of adjuvant usually, induces T cell priming and target Ag presentation by Langerhans cell migrating from the skin to the LN draining the immunization site. In this case, B cells and macrophages are not involved [Guery et al., 1996]. Similar results were obtained after sc or intradermic (id) DNA immunization for MHCII and MHCI-peptide complexes: dendritic cells can be directly transfected at the local site of injection and then migrate to the afferent LN via afferent lymphatics [Condon et al., 1996; Casares et al., 1997; Porgador et al., 1998]. The migration is known a key event of immunity since mechanical disruption of afferent lymphatics abrogates T cell response to skin sensitizers or skin grafts [Zinkernagel et al., 1997].

[0013] Therefore, targeting to dendritic cells is essen-

tial for CD4<sup>+</sup> and CD8<sup>+</sup> T cell stimulation. Since most antibody responses are dependent upon CD4<sup>+</sup> T cell help, targeting antigen to dendritic cells is a major goal in vaccination.

[0014] Applicants have been interested in studying the presentation of adenylcyclase of *Bordetella* species by T cell, and have identified a specific receptor molecule present on specific cells, that interacts with CyaA and opens new possibilities for the use of CyaA as a proteinaceous vector for molecules of interest.

[0015] Genetically detoxified bacterial toxins represent candidates as vaccine vectors, in particular for T epitope, due to their ability to invade eukaryotic cells [Ladant et al., 1999]. However, few proteinaceous vectors were shown to prime CTL responses *in vivo* [Ballard et al., 1996; Cabonette et al., 1999]. Moreover, despite numerous *in vitro* promising studies, no vector was shown to be exclusively targeted to pAPC and more particularly to myeloid dendritic cells.

[0016] The inventors have further shown that other cells, especially neutrophils, could be targeted by the vectors of the present invention.

[0017] The invention provides means that may at least in part, fulfil these needs and proposes new vectors that would specifically target molecules to determined populations of pAPC for example, to enable stimulating immune response.

[0018] Moreover, molecule targeted to the pAPC and specific leukocytes would enable the manufacturing of new vectors useful to deliver biologically active molecule to the proximal environment of these cells. These molecules, for example, could modulate the functional properties of the targeted cells or those involved in the immune response or in the inflammatory response.

[0019] Indeed, the inventors have found that *Bordetella pertussis* adenylcyclase toxin binds specifically with a cellular receptor designated (CD11b/CD18)  $\alpha_M/\beta_2$  receptor and that this interaction is required for the intracellular delivery of the adenylcyclase domain to the cytosol of cells and subsequent for cell death.  $\alpha_M/\beta_2$  (CD11b/CD18) integrin is a dimer of the  $\beta_2$  integrin family, the expression of these integrins being restricted to leukocytes. CD11b/CD18  $\alpha_M/\beta_2$  displays a pattern of expression in mouse and human, which is restricted to neutrophils/granulocytes, macrophages, dendritic cells, NK cells and subsets of B and T CD8<sup>+</sup> lymphocytes [Jeyaseelan et al., 2000; Amaout et al., 1990].

[0020] Therefore, this receptor would represent an ideal target for new vectors, designed in particular for T epitope immunization.

[0021] Applicants have shown in the present invention that the *Bordetella* adenylcyclase can be used to target a molecule *in vivo* specifically to CD11b expressing cells.

[0022] In particular, Applicants have shown in the present invention that a peptide antigen comprised in the *Bordetella pertussis* adenylcyclase toxin can efficiently be targeted specifically to the surface of dendritic

cells, translocated in the cytosol of said dendritic cells and prime a CTL response.

[0023] In a specific embodiment, said response is obtained bypassing adjuvant requirement and CD4<sup>+</sup> T-cell help.

[0024] This invention thus provides new efficient immunogenic composition as well as new drug delivery vector to CD11b expressing cells.

#### DETAILED DESCRIPTION OF THE INVENTION

[0025] This invention relates to the use of *Bordetella* adenylcyclase in the manufacturing of a proteinaceous vector for targeting a molecule of interest specifically to CD11b expressing cells.

[0026] The invention also relates to the use of a *Bordetella* adenylcyclase toxin wherein said adenylcyclase is recombined with an antigen of interest or conjugated to a molecule of interest for the preparation of a composition for the targeting of said peptide or molecule specifically to CD11b expressing cells.

[0027] The term "specifically" means within the context of the present invention that the adenylcyclase when used as a vector for a molecule of interest, is preferentially directed to CD11b expressing cells, thereby offering means to target the molecule of interest at the surface of said cells or within said cells in a selective way with respect to other cells.

[0028] In one embodiment of the invention, the molecule of interest is essentially directed to CD11b expressing cells.

[0029] As used herein, the term "CD11b expressing cells" relates to the cells that express the CD11b/CD18  $\alpha_m\beta_2$  receptor on their surface. In particular, in mouse, these cells are granulocytes/neutrophils, macrophages, NK cells, subsets of T CD8<sup>+</sup> and B cells and myeloid dendritic cells.

[0030] Since CD11b expressing cells and more specifically the myeloid dendritic cells, the neutrophils and the macrophages are involved in essential functions of the immune and innate defence system, in particular in inflammatory and specific immune responses, the invention relates to the manufacturing of a proteinaceous vector or a composition capable of targeting a molecule or a peptide of interest to these CD11b expressing cells.

[0031] In particular, in one embodiment, the targeting of said molecule or peptide is effective *in vivo*.

[0032] The invention thereby provides means appropriate for the design of compositions suitable for administration to animal or human hosts requiring targeting of certain leukocytes and in particular myeloid dendritic cells, neutrophils or macrophages.

[0033] As used herein, the term "*Bordetella* adenylcyclase" relates to the calmodulin-dependent adenylate cyclase secreted in *Bordetella* species or fragment thereof, said fragment retaining the function properties of the adenylcyclase, a major virulence factor mandatory for the initial phases of bacterial colonization in the

lung. The adenylate cyclase is synthesized and secreted in the form of a polypeptide of 1706 amino acids: The calmodulin-dependent catalytic activity is localized in the first 400 amino acids. In order to be active, said adenylcyclase toxin is rendered invasive and hemolytic when postraductionally modified by the product of the *CyaC* gene coexpression of the *cyaC* gene product.

[0034] The following specific features of *Bordetella* adenylcyclase toxin indicate that this toxin can be used in the manufacturing of a proteinaceous vector for targeting *in vivo* a molecule of interest to CD11b expressing cells:

a) this adenylate cyclase binds specifically to CD11b expressing cells

b) the N-terminal catalytic domain is translocated into the cytosol of those CD11b expressing cells.

c) the C-terminal domain binds to the membrane of CD11b expressing cells and could internalize by endocytic pathway.

[0035] Due to the specific interaction between *Bordetella* adenylcyclase toxin and CD11b/CD18  $\alpha_m\beta_2$  receptor, the molecule of interest is specifically targeted at least to the surface of CD11b expressing cells. In a particular embodiment of the invention, the *Bordetella* adenylcyclase toxin is used in the manufacturing of a proteinaceous vector to deliver the molecule of interest either in the cytosol of CD11b expressing cells, at the surface or into the endocytic pathway.

[0036] Expression vectors for the preparation of recombinant *Bordetella* adenylcyclase are described in patent application WO 93/21324 (Institut Pasteur). More specifically, expression vectors may be constructed directing the expression of both the *cyaA* gene and the *cyaC* gene (Sebo *et al.*, 1991). In parallel, a secondary plasmid carrying genes necessary for the secretion of the cytotoxic adenylcyclase in *E. coli*, such as *hlyB* and *hlyD* as described for example in Meckman *et al.*, 1985 can be constructed. In particular, the expression plasmid pCACT3 described in WO 93/21324 can be used. Using this plasmid, the adenylcyclase may be expressed in *E. coli* and possibly secreted by this bacterium in large amounts. It is also readily purified for example using affinity chromatography on CaM Affi-Gel resin or other published procedures, as those using DEAE-sepharose and phenyl-sepharose.

[0037] In one embodiment of the invention, the adenylcyclase is a recombinant genetically modified adenylcyclase. In particular, mutations such as point mutations, deletions or insertions can be obtained using usual site-directed or random mutagenesis techniques, provided that the domains necessary for binding to CD11b expressing cells and, optionally for translocation in the cytosol are still functional. Assays to evaluate specific binding of a recombinant toxin to CD11b expressing

cells and subsequent translocation of the catalytic domain are described in the following experimental part.

[0038] In another embodiment of the invention, the recombinant *Bordetella* species adenylcyclase comprises fragment of the native *Bordetella* species adenylcyclase, wherein said fragment is capable of binding the CD11b receptor.

[0039] More specifically, specific binding to CD11b can be assessed *in vitro* with anti-CD11b monoclonal antibodies as illustrated in the examples.

[0040] In order to be used in the manufacturing of proteinaceous vector or the preparation of a composition, the adenylcyclase is preferably non toxic. Non toxic mutants of the adenylcyclase toxin are well described in the Art. (Betsou et al. Infect. Immun. 1993 Sept., 6(9) 3583-3589; Betsou et al. Infect. Immun. 1995 Sept., 63(9) 3309-3315).

[0041] In a preferred embodiment of this invention, the adenylcyclase is isolated from *Bordetella pertussis*.

[0042] In specific embodiments, the molecule of interest is selected in the group comprising: lipopeptides, polysaccharides, oligosaccharides, nucleic acids, lipids and chemicals.

[0043] In specific embodiments, a molecule of interest is a heterologous antigen. As used herein, the term "heterologous" refers to an antigen derived from the antigen of a species other than the adenylcyclase which is used in the vector.

[0044] In a preferred embodiment of the invention, the manufacturing of the proteinaceous vector comprises the step of inserting a heterologous peptide in the catalytic domain of the adenylate cyclase at a permissive site.

[0045] As used herein, the term "permissive site" relates to a site where the heterologous peptide can be inserted without substantially affecting the desired functional properties of the adenylate cyclase toxin, i.e. without affecting the domains necessary for the specific binding to CD11b/CD18 receptor and advantageously without affecting the process of translocation of the catalytic domain. In a preferred embodiment, the capacity of the CyaA toxin to promote the synthesis of CAMP in the targeted cells is further maintained.

[0046] Methods to select for permissive sites are presented for example in WO93/21324 and in Ladant *et al.*, 1992. In particular, a methodology using a double selection (resistance to an antibiotic and calorimetric test on dishes by  $\alpha$ -complementation) enables to identify readily oligonucleotides insertions (which preserve the reading frame) in the portion of the gene coding for the N-terminal catalytic domain of the toxin. The functional consequences of these mutations on the catalytic activity of the toxin may be readily analysed, both genetically (functional complementation of an *E. coli cya*<sup>-</sup> strain) and biochemically (characterization of the stability of the modified adenylcyclases, of their enzymatic activity, of their interaction with caM, etc.). This methodology has enabled a large number of mutations to be screened in

order to identify the sites which are potentially advantageous for the insertion of antigenic determinants.

[0047] In specific embodiments of the invention, a permissive site is selected from the group consisting of residues 137-138, residues 224-225, residues 228-229, residues 235-236 and residues 317-318 of the *Bordetella pertussis* adenylate cyclase.

[0048] However, other permissive sites may be used in the present invention, that can be identified by use of the methodology indicated above, especially sites between 400 and 1700.

[0049] In a preferred embodiment of the invention, the adenylcyclase is used in the manufacturing of the proteinaceous vector or in the preparation of the composition specifically designed to prime CD8<sup>+</sup> cytotoxic T-cell response (CTL response) said response follows the targeting of the adenylcyclase modified (especially recombined or conjugated) with a molecule of interest to CD11b expressing cells, followed by the translocation of the molecule of interest to the cytosol of said CD11b expressing cells, and in particular to myeloid dendritic cells. In this context, the molecule of interest is or comprises preferably an epitope or an antigen.

[0050] As used herein, the term "epitope" refers to a heterologous peptide that can induce an immune response.

[0051] In specific embodiments, the antigen is selected from the group consisting of an intracellular bacterial cell antigen, a tumoral cell antigen, a viral antigen, a fungus antigen or a parasite cell antigen.

[0052] In a preferred embodiment of the invention, the adenylcyclase is used in the manufacturing of the proteinaceous vector or in the preparation of the composition specifically designed to prime CD4<sup>+</sup> cells response (CTL response) said response follows the targeting of the adenylcyclase modified (especially recombined or conjugated) with a molecule of interest to CD11b expressing cells, followed by the translocation of the molecule of interest to the cytosol of said CD11b expressing cells, and in particular to myeloid dendritic cells. In this context, the molecule of interest is or comprises preferably an epitope or an antigen.

[0053] A molecule of interest can be especially an antigen selected from the group consisting of: a poliovirus antigen, an HIV virus antigen, an influenza virus antigen, a choriomeningitis virus epitope.

[0054] The functional properties of the CD11b expressing cells define furthermore a novel use of the *Bordetella* adenylcyclase toxin in the manufacturing of a proteinaceous vector for drug targeting to these specific cells. In this context, in one specific embodiment of the invention, the so-called molecule of interest is a drug. Said drug may be chemically or genetically coupled to the adenylcyclase. Method for coupling a drug to a polypeptide are well known in the Art and comprise for example disulfide linkage wng N-pgrd sulfonyl-activated sulphydryl.

[0055] Advantageously, a molecule of interest is an

anti-inflammatory drug which is, when coupled to the adenylcyclase toxin, specifically targeted to the surface of the cells involved of the inflammatory response, such as neutrophils.

[0056] It is shown for the first time in the experimental part of the present text, that a genetic insertion of an antigen into a detoxified form of *Bordetella* adenylcyclase toxin allows its *in vivo* targeting to the cytosol of CD11b+ antigen presenting cells.

[0057] More specifically, antigen presentation for selective CD8+ cytotoxic cells priming is mainly performed by myeloid dendritic cells.

[0058] Applicant have also shown that CTL specific for the vectorized antigen can be primed *in vivo* after a single intravenous injection of the recombinant toxin, especially with no need to provide an heterologous adjuvant. These results shown in the experimental part and in particular the specific targeting of the epitope to myeloid dendritic cells enable new immunization strategies that bypass the requirement for adjuvant and CD4+ T cell help.

[0059] Therefore, the invention also relates to the use of a *Bordetella* adenylcyclase toxin recombined with a peptide of interest for the preparation of a composition formulated for intravenous administration and enabling a CD8+ T cell immune response *in vivo*, said composition being free of a heterologous adjuvant. The invention also concerns this composition as such.

[0060] The invention in particular also relates to a new immunogenic composition formulated for intravenous administration in an animal or human host, characterized in that it comprises a recombinant *Bordetella* adenylcyclase which comprises an antigen inserted in the catalytic domain.

[0061] The invention further relates to a pharmaceutical composition for administration in a human or an animal formulated for targeting a molecule of interest specifically to CD11b expressing cells characterized in that said molecule of interest is coupled to a *Bordetella* species adenylcyclase.

[0062] In one preferred embodiment, the molecule of interest is selected in the group comprising: lipopeptides, polysaccharides, oligosaccharides, nucleic acids, lipids and chemicals.

[0063] In another preferred embodiment, the molecule of interest is an antigen.

[0064] In another specific embodiment, The pharmaceutical or immunogenic composition comprises a nucleic acid construction encoding the recombinant *Bordetella* species adenylate cyclase comprising a recombinant *Bordetella* species adenylate cyclase coupled to a molecule of interest.

[0065] In specific embodiments, the adenylcyclase is from *Bordetella pertussis* toxin.

[0066] In other specific embodiments, the adenylcyclase toxin is a genetically modified toxin recombinant toxin from *Bordetella pertussis*. In one preferred embodiment, the adenylcyclase is a non toxic adenylcyclase,

especially a detoxified adenylcyclase.

[0067] In one preferred embodiment, the genetically modified adenylcyclase retains the ability to translocate the molecule of interest specifically in the cytosol of CD11b expressing cells.

[0068] In a preferred embodiment, the antigen is inserted in the permissive sites selected from the group consisting of residues 137-138, residues 224-225, residues 228-229, residues 235-236 and residues 317-318 of the *Bordetella pertussis* adenylate cyclase.

[0069] In a specific embodiment, the antigen is an intracellular bacterial cell antigen, a tumoral cell antigen, a viral antigen, a fungus antigen or a parasite cell antigen.

[0070] In preferred embodiments, a molecule of interest is an antigen selected from the group consisting of: a poliovirus epitope, an HIV virus, an influenza virus antigen, a choriomeningitis virus antigen.

[0071] In another embodiment, the genetically modified toxin retains the ability to deliver the molecule of interest specifically at the surface of CD11b expressing cells or into the endocytic pathway.

[0072] The applicants have shown that *in vivo* intravenous administration of the immunogenic composition in an animal or human host as defined in the present invention without adjuvants is sufficient to promote efficiently an immune response in said animal or human host.

[0073] As a consequence, in a specific embodiment, the immunogenic or pharmaceutical composition is advantageously devoid of priming adjuvants commonly used in the Art, such as aluminium hydroxide.

[0074] In one specific embodiment, the molecule of interest is a drug, preferably an anti-inflammatory drug.

[0075] Furthermore, the invention also relates to the use of the immunogenic composition as defined above for the preparation of a vaccine or an immunotherapeutic composition, for administration to an animal or human host.

[0076] As used herein, the term "immunotherapeutic composition" relates to a composition which leads to an immunological response and which is associated to therapeutic treatments, such as treatment against cancers, viral infections, parasites infections or bacterial infections.

[0077] The invention further relates to a method to immunize an animal or human host, wherein said method comprises the steps of:

a) providing an immunogenic composition as defined above;

b) administering said immunogenic composition via intravenous route to said host in order to promote an immune response.

[0078] The invention finally relates to a proteinaceous vector for delivery of a molecule of interest, specifically

to CD11b expressing cells, characterized in that said vector comprises a *Bordetella* species adenylcyclase coupled to said molecule of interest.

[0079] The proteinaceous vector is able to target a molecule of interest to CD11b expressing cells via the specific binding of *Bordetella* adenylcyclase with CD11b/CD18  $\alpha_m\beta_2$  which is present on the surface of specific cells. In one specific embodiment, the vector is also able to deliver the molecule of interest specifically in the cytosol of CD11b expressing cells.

[0080] In specific embodiments, the proteinaceous vector is able to target a molecule of interest to myeloid dendritic cells or to neutrophils.

[0081] The molecule of interest is chemically or genetically coupled to the adenylcyclase toxin. Method for coupling a molecule to a polypeptide are well known in the Art. As an example, the inventors showed that a biotin derivative, biotin HDPD can be selectively coupled on a unique cysteine residue genetically inserted within the catalytic domain. Synthetic peptides have been coupled similarly to the cysteine containing adenylate cyclase toxin.

[0082] In a specific embodiment, the proteinaceous vector comprises a genetically modified adenylcyclase. In one preferred embodiment, the adenylcyclase is a recombinant non toxic adenylcyclase from *Bordetella pertussis*.

[0083] Advantageously, in one specific embodiment of the invention, a drug to be delivered is an anti-inflammatory drug which is, when coupled to the adenylcyclase toxin, targeted to the surface or to the cytosol of the cells involved of the inflammatory response, such as neutrophils.

[0084] The following examples will illustrate the present invention without limiting the scope of the claimed invention. More specifically, in part A, experimental data are shown that reveal the specific binding of adenylcyclase toxin to CD11b/CD18 receptor, and in particular the specific binding of adenylcyclase toxin to CD11b expressing cells *in vitro*. In part B, the experimental results show the possibility to target an antigen *in vitro* and *in vivo* specifically to the cytosol of CD11b expressing cells, and in particular to myeloid dendritic cells. Moreover, the results show that the targeting is mediated by the CD11b receptor and that CTL priming is observed after systemic immunization in the absence of adjuvant.

[0085] Finally, the results indicate that, unlike many other CTL responses as those raised against cross-priming antigen, CD4+ T cell help was not mandatory for priming of CTL responses.

## LEGENDS TO FIGURES

**Figure 1: Saturable binding of CyaA correlates with CD11b expression**

[0086] **a:** CyaA binding at the surface of macrophages

(J774A.1), B cells (LB27.4), and T cells (EL4) was performed at 37°C for 20 minutes. Surface-bound CyaA was detected with a biotinylated anti-CyaA polyclonal antibody, revealed by streptavidin-PE and detected by flow cytometry on living cells, as described in the material and methods section. Binding is expressed as  $\Delta\text{MFI} = (\text{mean fluorescence intensity value of cells incubated with CyaA}) - (\text{mean fluorescence intensity of cells without CyaA})$ .

[0087] **b, c, d, e:** Surface expression of  $\beta_2$  integrins on J774A.1, LB27.4 and EL4 cells. CD11a (b), CD11b (c), CD11c (d), and CD18(e) expression were determined by flow cytometry using specific mAbs coupled to PE. Integrin expression is expressed as  $\Delta\text{MFI} = (\text{mean fluorescence intensity value of cells stained with specific mAb}) - (\text{mean fluorescence intensity of cells stained with an isotype control mAb})$ .

**Figure 2: CyaA binding to murine cell lines is blocked by anti-CD11b mAb.**

[0088] Cells were preincubated at 4°C for 15 minutes with or without 20  $\mu\text{g/ml}$  of specific mAbs and then incubated at 4°C for 20 minutes with 5  $\mu\text{g/ml}$  CyaA and with 10  $\mu\text{g/ml}$  of specific mAbs if present during the preincubation. Surface-bound CyaA was detected with a biotinylated anti-CyaA polyclonal, revealed by streptavidin-PE and detected by flow cytometry on living cells, as described in the material and methods section.

[0089] **a, b:** Effect of the M1/70 anti-CD11b mAb on the binding of various doses of CyaA. FSDC dendritic cells (a) or J774A.1 macrophages (b) were preincubated with medium alone (○) or with M1/70 anti-CD11b mAb (●) and then incubated with CyaA with or without M1/70 anti-CD11b mAb. Bmax was determined by fitting experimental points obtained from experiments performed without mAbs to  $\Delta\text{MFI} = \text{Bmax} \cdot [\text{CyaA}] / (K_d + [\text{CyaA}])$ . Binding of CyaA is plot as a % of Bmax plot against CyaA concentration.

[0090] **c, d:** Effect of specific mAbs on a fixed dose of CyaA binding. FSDC (c) or J774A.1 (d) cells were preincubated with or without specific mAbs (anti-CD11a, 2D7, antiCD11b, M1/70 and 5C6, anti-CD11c, HL3, anti-CD18, C17/16, control A95-1) and incubated with CyaA at the fixed concentration of 5  $\mu\text{g/ml}$ . Values of  $\Delta\text{MFI}$  obtained for CyaA binding on cells treated with specific mAbs were normalized as  $\Delta\text{MFI}$  values obtained for CyaA binding without mAb.

**Figure 3: CyaA binding to the human neutrophils is blocked by anti-CD11b and anti-CD18 mAbs.**

[0091] **a, b, c:** Fluorescence histograms of freshly purified neutrophils were preincubated with medium alone (a), the 44 anti-CD11b mAb (b) or an isotype-matched control mouse mAb (c) and then incubated with (gray) or without (blank) of biotinylated CyaA and revealed by streptavidine-PE. Cell number is plotted against log of

PE fluorescence.

[0092] **d**: Effect of specific mAbs on CyaA binding to neutrophils (anti-CD11b, 44, M1/70, anti-CD18, TS/18, control mouse IgG2a, control rat IgG2b, A95-1). Freshly purified neutrophils were preincubated with or without specific mAbs and incubated with CyaA. Values of  $\Delta$ MFI obtained for CyaA binding on cells treated with specific mAbs were normalized as a % of the  $\Delta$ MFI values obtained for CyaA binding without mAb.

**Figure 4**: Intracellular cAMP increase and cell death mediated by CyaA are specifically blocked by an anti-CD11b mAb in J774A.1 cells.

[0093] **a**: Effect of specific mAbs on intracellular cAMP accumulation. J774A.1 cells were preincubated at 4 °C for 1 h with or without 10  $\mu$ g/ml of specific mAbs (anti-CD11b, M1/70, anti-CD18, C17/16) and then incubated at 37 °C for 20 min with 5  $\mu$ g/ml CyaA and with 10  $\mu$ g/ml mAbs if present during the preincubation. Intracellular cAMP contents were determined as described in the materials and methods section.

[0094] **b**: Effect of specific mAbs on CyaA mediated cell death. J774A.1 cells were preincubated at 4 °C for 1 h with medium alone or with 10  $\mu$ g/ml of specific mAbs (anti-CD11a, 2D7 anti-CD11b, M1/70, anti-CD11c, HL3, anti-CD18, C71/16, control, 2.4G2). Then they were incubated at 37 °C for 2 h with 0.5  $\mu$ g/ml CyaA and with 10  $\mu$ g/ml of specific mAbs when present during the preincubation. Cell lysis was determined by LDH release using the Cytotox 96™ assay.

**Figure 5**: CHO cells bind CyaA and become sensitive to CyaA when transfected with CD11b, but not with CD11c

[0095] **a, b**: CyaA binding at the surface of CHO transfectants. CHO cells transfected with human CD11b/CD18 (●), human CD11c/CD18 (○) or mock-transfected (●) were incubated with various doses of CyaA for 20 min at 37°C (a) or 4°C (b). Surface-bound CYAA was detected with a biotinylated anti-CyaA polyclonal antibody, revealed by streptavidin-PE and detected by flow cytometry on living cells, as described in the material and methods section. Binding is expressed as  $\Delta$ MFI = (mean fluorescence intensity value of cells incubated with CyaA) - (mean fluorescence intensity of cells without CyaA).

[0096] **c**: Intracellular cAMP accumulation in CHO transfectants. CHO cells transfected with human CD11b/CD18 (●), human CD11c/CD18 (○) or mock-transfected (●) were incubated with or without CyaA for 20 min at 37°C. Intracellular cAMP contents were determined as described in the materials and methods section.

[0097] **d**: Cell lysis in CHO transfectants. CHO cells transfected with human CD11b/CD18, human CD11c/CD18 or mock-transfected were incubated with 5 g/ml

CyaA for 4 h at 37 °C. Cell lysis was determined by LDH release using the Cytotox 96™ assay.

**Figure 6**: Intravenous immunization with CyaAOVA primes anti-OVA CTL responses in a B cell, CD4 and CD40-independent way.

[0098] C57BL/6 WT +/+ (a), CD4-/- (b), CD40-/- (c) or IgM-/- (d) mice were intravenously immunized with 50  $\mu$ g of CyaAOVA, a genetically detoxified form of CyaA carrying the H-2K<sup>b</sup> restricted SIINFEKL epitope from OVA (●, ○) or with CyaAE5, a control detoxified toxin without the OVA epitope (▲, △). Seven days after, animals were sacrificed and splenocytes were restimulated *in vitro* for 5 days with 10  $\mu$ g/ml of the pOVA synthetic peptide in the presence of irradiated C57BL/6 splenocytes. CTL activity was assessed in a 4 hours chromium<sup>51</sup> release assay against H-2K<sup>b</sup> EL4 cells previously pulsed (●, ▲) or not (○, △) with pOVA at 10  $\mu$ g/ml.

**Figure 7**: Identification of splenic antigen presenting cells involved in CyaAOVA presentation *in vitro* or *in situ*, after intravenous immunization.

The low density fraction of splenocytes presents CyaAOVA to a specific anti-OVA CD8+ T cell hybridoma (a, b):

[0099] *In vitro* assay (a): Low (LDF, ●) and high density (HDF, ▲) fractions or unfractionated total splenocytes from naive mice (TSC, ■, □) were cultured with B3Z, a CD8+ T cell hybridoma specific for the pOVA peptide in the context of H-2K<sup>b</sup>. After 18 hours of coculture in the presence of the recombinant detoxified CyaA carrying the OVA peptide (CyaAOVA, ●, ▲, ■) or a control peptide (CyaALCMV, □) at various concentrations, IL-2 released in supernatants was measured in a CTL proliferation assay.

[0100] Results are expressed in  $\Delta$ cpm and plotted against CyaA concentration during the assay  $\Delta$ cpm = [cpm + CyaA] - [cpm - CyaA].

[0101] *Ex vivo* assay (b): Spleen cells were obtained from mice previously immunized *iv* (6-12 hours) with 50  $\mu$ g of CyaAOVA (●, ▲, ■) or CyaALCMV (○) and fractionated in LDF and HDF. Various numbers of cells recovered from TSC (■), LDF (●, ○) or HDF (▲) or unfractionated splenocytes (■) were directly put in culture with B3Z without addition of recombinant CyaA. IL-2 release was assessed after 18 hours of culture as described before. Results, expressed in cpm, are plotted against the number of APC present in each well.

Dendritic cells (CD11c<sup>+</sup>) are more efficient APC for CyaAOVA than the CD11b<sup>high</sup>CD11c<sup>-</sup> cells or B cells (CD45R<sup>+</sup>) (c,d):

[0102] *In vitro* assay (c): CD11c<sup>+</sup> (●) sorted cells from

LDF, CD11b<sup>high</sup>CD11c<sup>-</sup> (○) and CD45R<sup>+</sup> (■) sorted cells from TSC, were put in culture with B3Z for 18 hours in the presence of various concentrations of CyaAOVA. IL-2 was assessed as above.

[0103] *Ex vivo* assay (d): Cells sorted by flow cytometry from C57BL/6 mice previously (6-12 hours) immunized with 50 µg of CyaAOVA were used as APC. CD11c<sup>+</sup> (●), CD11b<sup>high</sup>CD11c<sup>-</sup> (○), CD45R<sup>+</sup> (■) sorted cells from low density splenocytes were directly put in culture for 18 hours with B3Z at various numbers of cells per well, without addition of CyaAOVA. IL-2 was assessed as above.

**The CD8α<sup>+</sup> myeloid dendritic cell subset is a more efficient APC for CyaA than the CD8α<sup>+</sup> lymphoid dendritic cell subset (e, f):**

[0104] CD11c<sup>+</sup> low density cells from naive mice (e) or mice previously (6-12 hours) immunized iv with 50 µg CyaAOVA (f) were fractionated in myeloid dendritic cells (CD11c<sup>+</sup>CD8α<sup>-</sup> ●) and lymphoid dendritic cells (CD11c<sup>+</sup>CD8α<sup>+</sup> ○) by flow cytometry and used as APC in *in vitro* (e) and *ex vivo* (f) assays for B3Z stimulation. IL-2 was assessed as above.

**B cell genetic depletion does not impair CyaAOVA presentation by splenocytes (g, h):**

[0105] TSC (■, □), LDF (●, ○) or HDF (▲, Δ) from C57BL/6 WT mice (■, ●, ▲) or B cell deficient (□, ○, Δ) were used as APC in an *in vitro* assay (g, ■, □) or an *ex vivo* assay (h, ●, ○, ▲, Δ) for B3Z stimulation as in a. Mice were either from naive (g) or previously (1.5 hours) immunized iv with 50 µg CyaAOVA (h). IL-2 was assessed as above.

**Figure 8: The presentation of CyaAOVA by dendritic cells requires the TAP transporters *in vitro* and *in vivo* after intravenous immunization.**

[0106] *In vitro* assay (a): TSC (▲, Δ) or CD11c<sup>+</sup> (●, ○) sorted cells from control C57BL6 TAP<sup>+/+</sup> (▲, ●) or TAP<sup>-/-</sup> mice (Δ, ○) were cultured with B3Z in the presence or not of various doses of CyaAOVA. IL-2 was assessed as described in figure 6a. Results are expressed in cpm plotted against antigen concentration.

[0107] *Ex vivo* assay (b): TSC (▲, Δ) or CD11c<sup>+</sup> (●, ○) sorted cells from control C57BL6 TAP<sup>+/+</sup> (▲, ●) or TAP<sup>-/-</sup> mice (Δ, ○) previously iv immunized with 50 µg of CyaAOVA were cultured with B3Z for 18 hours. IL-2 was assessed as described in figure 6a. Results are expressed in cpm plotted against the number of cocultured cells.

**Figure 9: Role of α M β2 integrin (CD11b) in CyaAOVA binding to cells.**

[0108] *Binding of CyaAOVA-biotine to TSC is blocked*

*by anti-CD11b (a):* TSC suspensions were incubated at 4°C with 10 µg/ml of the anti-CD11b M1/70 mAb or an isotype control mAb or nothing. Then, CyaAOVA-biotine at 2 µg/ml (left pannels) or various concentrations (right pannel) was added to the cells for 30 mn at 4°C. After a wash, CyaAOVA-biotine was revealed with streptavidine-PE for 30 mn (Strep-PE). Then, after washing, cells were resuspended in PBS containing propidium iodide. The size (FSC) of living cells gated by propidium iodide exclusion was plotted against the Strep-PE fluorescence. The percentage of leukocytes positive for CyaAOVA-biotine was plotted against CyaAOVA-biotine concentration during the staining.

[0109] *Binding of CyaAOVA-biotine to low density cells correlates with the expression of CD11b (b):* LDF were triple stained for CD11c, CD8 α and CyaOVBiotine (or medium) or, in separate experiments with CD11c, CD8α and CD11b (or a control mAb). After a wash, cells were stained for 30 mn with Strep-PE to reveal CyaAOVA-biotine, anti-CD11c-FITC and anti-CD8α-APC. Gates were done on lymphoid DC (CD11c<sup>+</sup>CD8 α<sup>+</sup>), myeloid DC (CD11c<sup>+</sup>CD8 α<sup>-</sup>), CD8<sup>+</sup> T cells (CD11c<sup>-</sup>CD8 α<sup>+</sup>) and other cells (CD11c<sup>-</sup>CD8 α<sup>-</sup>). For each gate, CyaAOVA-biotine staining or CD11b staining is plotted against cell number in separate histograms. Left histograms: LDF suspensions were incubated with 0 (histograms filled in grey), 2.5 (narrow, open histograms) or 10 µg/ml (thick, open histograms) of CyaAOVA-biotine for 30 minutes at room temperature. Right histograms: isotype control-PE (histogram filled in grey), CD11b-PE (thin, open histograms).

**Figure 10: Role of α M β2 integrin (CD11b) in CyaAOVA presentation by MHC I**

[0110] *In vitro* antigen presenting assay with TSC (a, b): The same experiments than in a, b were performed with TSC from naive C57BL/6 mice as APC. The stimulation of B3Z was assessed by IL-2 release in coculture supernatants measured in a CTLL proliferation assay. Results are plotted in cpm against CyaAOVA or pOVA concentration.

[0111] *Ex vivo* antigen presenting assay with TSC or CD11b<sup>+</sup> and CD11b<sup>-</sup> fractions (c, d): C57BL/6 mice were intravenously immunized with 50 µg of CyaAOVA (c) or 10 µg of pOVA (d). CD11b<sup>+</sup> (●) and CD11b<sup>-</sup> (○) cells were sorted by flow cytometry from TSC (Δ) and put in culture at various cell number per well with B3Z. After 18 hours of coculture, the stimulation of B3Z was assessed by IL-2 release. Results, expressed in cpm, are plotted against the numbers of APC from immunized animals present in each well.

## EXAMPLES

### A. The bordetella adenylate cyclase toxin interacts specifically with the $\alpha_M\beta_2$ integrin (CD11b/CD18)

#### A.1 Materials and Methods

##### A.1.1 Recombinant toxins and antibodies

[0112] Protocol for CyaA production has already been described elsewhere [Karimova, et al, 1998]. CyaA toxins were produced in *E. coli* BLR strain harboring an expression plasmid, pCACT3, which carries the cyaA structural gene CyaA under the lacUV5 promoter and the cyaC accessory gene required for activation of the protoxin. After solubilization in 8M urea, Hepes-Na 20mM, pH 7.5, CyaA was purified to more than 95% homogeneity (as judged by SDS-gel analysis, not shown) by sequential DEAE-Sepharose and Phenyl-Sepharose. A recombinant detoxified CyaA toxin, CACTE5-Cys-Ova, harboring a unique cysteine inserted within the genetically inactivated catalytic domain was constructed by inserting an appropriate double strand oligonucleotide between the BsiwI and KpnI sites of pCACT-Ova-E5 [Guermontprez et al, 2000]. In the resulting protein CACTE5-Cys-Ova, the amino acid sequence ASCGSIINFEKLGIT is inserted between residues 224 and 225 of CyaA. The recombinant toxin was expressed and purified as previously described. The purified protein was labeled on its unique Cys with the highly specific sulfhydryl reagent N-(6-(Biotinamido)hexyl)-3'-(2'-pyridyldithio) propionamide (Biotin-HPDP, PIERCE) according to the manufacturer's instructions. The biotinylated-CyaA was re-purified on DEAE-Sepharose to remove the unreacted Biotin-HPDP reagent. Toxin concentrations were determined spectrophotometrically from the adsorption at 280 nm using a molecular extinction coefficient of  $142 \text{ M}^{-1} \times \text{cm}^{-1}$  (binding studies) or using the Biorad protein assay system (cAMP accumulation and cell death studies).

[0113] Purified mAbs specific for murine CD11a (2D7, Rat IgG2a,  $\kappa$ ), murine and human CD11b (M1/70, Rat IgG2b,  $\kappa$ ), murine CD11c (HL3, Hamster 1,  $\lambda$ ), murine CD18 (C71/16, Rat IgG2a,  $\kappa$ ), control (A95-1, or anti-CD16/32, 2.4G2, Rat IgG2b,  $\kappa$ ) originated from Pharmingen (San Diego, USA). Supernatants from anti-human CD11b (44, Mouse IgG2a,  $\kappa$ ), and anti-human CD18 (TS/18, Mouse IgG1,  $\kappa$ ) hybridoma were a kind gift and were used at 1/2 dilution in blocking experiments. Supernatants from an anti-murine CD11b (5C6, Rat IgG2b,  $\kappa$ ) were a kind gift from G. Milon (Pasteur Institute, Paris) and were used at 1/2 final dilution in binding inhibition assays. Anti-CyaA polyclonal antibodies were obtained from a rabbit immunized subcutaneously with purified CyaA. Sera were precipitated from immune serum by ammonium sulfate (33%). After centrifugation the pelleted proteins were resuspended in 20 mM Hepes-Na, 150 mM NaCl, pH 7.5 (buffer C) and ex-

tensively dialysed against the same buffer. The antibodies were then biotinylated by incubation with Biotin-aminocaproate N-Hydroxysuccinimide ester (SIGMA, dissolved in dimethyl sulfoxide) for 130 min at room temperature. Then, 100 mM ethanolamine, pH 9.0 were added and after 30 min of additional incubation, the mixture was extensively dialysed at 4 °C against buffer C. Biotinylated antibodies were stored at -20°C.

##### A.1.2 Cells and culture media

[0114] EL4, J774A.1, LB27.4, THP-1 were obtained from the American Type Culture Collection (ATCC) and were cultured in RPMI 1640 supplemented with 10% fetal calf serum, 100 U/ml penicillin, 100  $\mu\text{g}/\text{ml}$  streptomycin, 2mM L-glutamine, with or without  $5 \times 10^{-5} \text{ M}$  2-mercaptoethanol (complete medium). FSDC [Girolomoni et al, 1995] were cultured in complete medium. CHO cells transfected for human CD11b/CD18 or CD11c/CD18 or transfected with the vector only were obtained from D. Golenbock (Boston, USA) and cultured in the presence of neomycin as previously described [Ingalls et al, 1998]. Human neutrophils were purified as previously described [Rieu et al, 1992].

##### A.1.3 CyaA binding assays

[0115] All binding assays were performed in DMEM 4.5 mg/ml glucose (Life Technologies) without serum in 96 well culture plates (Costar).  $2 \times 10^5$  cells/well were incubated for 20 minutes (at 4°C or 37°C depending on the experiments) in a 200  $\mu\text{l}$  final volume. In some experiments, cells were preincubated for 20 min at 4°C in the presence of blocking mAbs in 100  $\mu\text{l}$  final volume. The toxin solution was added to the wells in the continuous presence of the mAbs in a total volume of 200  $\mu\text{l}$  at 4°C. Then, plates were centrifuged at 1500 rpm for 5 min and supernatants were removed. Cells were incubated at 4°C for 25 minutes with biotinylated anti-CyaA rabbit polyclonal antibodies (1/400 in DMEM, 50  $\mu\text{l}/\text{well}$ ) in the presence of a control (non-immune or pre-immune) rabbit serum as a saturating agent (1/50).

[0116] After centrifugation and supernatant removal, cells were stained with streptavidin-phycoerythrin (PE) (Pharmingen) at 1/300 dilution (50  $\mu\text{l}/\text{well}$ ). After washing, cells were analyzed by flow cytometry on a FACStar (Becton-Dickinson, Mountain View, USA) in the presence of 5  $\mu\text{g}/\text{ml}$  propidium iodide. Gatings were done to exclude cells aggregates and dead cells by propidium iodide exclusion. Experimental points were fitted to a hyperbolic model  $\Delta\text{MFI} = \text{Bmax} \times [\text{CyaA}] / (K_d + [\text{CyaA}])$ , with Bmax = % of maximal binding, using the prism software.

##### A.1.4 cAMP assay

[0117] cAMP accumulation was measured by an antigen competition immunoassay [Karimova et al, 1998] in which the incubation medium was composed of

DMEM without serum but containing 4.5 mg/ml glucose and 20 U/ml hexokinase. Hexokinase, which catalyzes the ATP-dependent phosphorylation of glucose, was added to deplete the extracellular medium for any traces of ATP, thus preventing the extracellular synthesis of cAMP. Therefore, the amount of cAMP measured is representative of the accumulation of strictly intracellular cAMP.  $5 \times 10^5$  cells were preincubated in 96 well plates in 100  $\mu$ l/well with or without 10  $\mu$ g/ml of specific mAbs at 4 °C for 1 h and then incubated at 37 °C for 20 min with 0.05, 0.5 or 5  $\mu$ g/ml CyaA and with 10  $\mu$ g/ml of specific mAbs when present during the preincubation. For the dose response effect of CyaA, cells were directly incubated with the toxin for 20 min at 37 °C. After intoxication, cells were centrifuged at 2,500 rpm for 5 min. Samples were lysed with 100  $\mu$ l of HCl 0.1 N, boiled for 5 min at 120 °C, and neutralized with 100  $\mu$ l of Tris 0.125 M, NaCl 0.2 M. Microtiterplates were coated with cAMP-BSA conjugates diluted at 1/4,000 in Na<sub>2</sub>CO<sub>3</sub> 0.1 M pH 9.5. They were washed twice in PBS-Tween 0.1 %, saturated for 1 h in PBS-BSA 2 % and washed five times with PBS-Tween 0.1 %. The samples and the cAMP standard (Sigma) were directly added to the plates coated with cAMP-BSA conjugates and serially diluted with a 1/1 mixture of HCl 0.1 N and Tris 0.125 M- NaCl 0.2 M. Anti-cAMP rabbit antibody was added at 1/2,500 in PBS-BSA 2 % and incubated at 37 °C for 3 h. Plates were washed five times with PBS-Tween 0.1 %. Anti-rabbit antibodies coupled to horseradish peroxidase (Amersham) were added at 1/2,500 in PBS-BSA 2 %, incubated at 37 °C for 1 h and revealed using the classical peroxidase reaction. Experimental points of the standard curve were fitted to a sigmoid model using the Prism software.

#### A.1.5 Toxicity assay

[0118] Cell death was evaluated as previously described [Khelef et al, 1993 ; Khelef et al, 1995]. Briefly,  $10^5$  cells were incubated for 24 hours in a 96 well plate in complete medium and washed once with serum free medium. All cell incubations were further performed in serum free medium. Dose response effects were evaluated by directly applying various concentrations of CyaA to CHO cells at 37 °C for 4 h. For cytotoxicity inhibition, cells were preincubated at 4 °C for 1 h with or without 10  $\mu$ g/ml of specific mAbs and then incubated at 37 °C with 0.5  $\mu$ g/ml CyaA for 2 h for J774A.1A.1 cells or with 5  $\mu$ g/ml for 4 h for CHO cells and with 10  $\mu$ g/ml of specific mAbs when present during the preincubation. Cell lysis was evaluated using the Cytotox 96™ assay (Promega) which quantifies the amount of lactate dehydrogenase (LDH) released in the medium by dying cells.

## A.2 Results

### A.2.1 Saturable binding of CyaA correlates with the presence of CD11b at the surface of target cells

[0119] To characterize CyaA cellular specificity toward a population of leukocytes, we chose three representative murine cell lines expressing various combination of  $\beta_2$  integrins: J774A.1, a tumoral macrophage; EL4, a T cell thymoma, and LB27.4, a B cell lymphoma. After a 20 minutes of incubation with CyaA at 37 °C, binding of CyaA to the cell surface of these cells was monitored by flow cytometry using biotinylated anti-CyaA antibodies and streptavidine-PE. Under these conditions, we observed an efficient, dose-dependent and saturable binding of CyaA on J774A.1 cell line. The affinity of CyaA for J774A.1 cells was high since the apparent  $K_d$  were  $9.2 \pm 4.5$  nM and  $3.2 \pm 1.9$  nM, respectively. A low binding of CyaA to EL4 and LB27.4 cells was observed but it was not saturable at the concentrations tested.

[0120] In order to determine if the binding of CyaA to J774 cell lines was correlated to the expression of one of the members of the  $\beta_2$  integrin family, we performed a phenotypic analysis of these cells by flow cytometry using monoclonal antibodies (mAbs) specific for the three  $\alpha$  chains of the well characterized  $\beta_2$  integrins (CD11a, CD11b and CD11c) and for the common  $\beta$  chain (CD18) (Figure 1b, c, d, e). J774A.1 cells expressed mostly CD11b and CD18, but were also positive for CD11a. EL4 cells and LB27.4 cells expressed mostly CD11a and CD18. Taken together, these data show that the efficient and saturable binding of CyaA to J774A.1 was correlated with the presence of the integrin CD11b/CD18.

### A.2.2 CyaA saturable binding is specifically blocked by anti-CD11b mAbs

[0121] We next examined if CD11b/CD18 could be directly involved in the binding of CyaA to the cells expressing this integrin. We performed a quantitative analysis of inhibition obtained with anti-CD11b M1/70 mAb by calculating percentage of mean fluorescence values in the absence of mAbs at a fixed or varying concentrations of CyaA (figure 2). Inhibition of CyaA binding obtained with the M1/70 anti-CD11b mAb was almost total at most CyaA concentrations tested (figure 2a, b). This inhibition was specific since anti-CD11a, CD11c, CD18 or a control mAb did not inhibit CyaA binding. A second anti-CD11b mAb (clone 5c6) also inhibited binding of CyaA (figure 2 c,d). Similar results were obtained with FSDC, an immature dendritic cell line expressing CD11b (figure 2a, c), and the J774A.1 macrophage cell line (figure 2b, d).

[0122] To examine whether CyaA could similarly interact with human CD11b, CyaA binding studies were performed on human neutrophils, whose high expres-

sion of CD11b is well established. Since high background fluorescence was obtained following incubation of human myeloid cells with the anti-CyaA rabbit antibodies (data not shown), we set up an alternate binding assay. A detoxified form of CyaA was specifically biotinylated on unique cysteine residues, genetically introduced within its catalytic domain. Using this system, we were able to detect CyaA binding to neutrophils (Figure 3). Preincubation of neutrophils with the 44 or M1/70 anti-CD11b mAbs led to, a respectively complete or partial inhibition of the binding of CyaA (Figure 3a and b). Unlike the C71/16, anti-murine CD18 mAb that did not block CyaA binding to murine cells, preincubation with the human anti-CD18 TS/18 mAb led to a complete inhibition of CyaA binding to human neutrophils (Figure 3b). Similar results were obtained with the human monocytic THP-1 cell line (data not shown).

[0123] In conclusion, CyaA binding to the surface of three myeloid cell lines from both murine and human origin (J774A.1, FSDC, THP-1) as well as freshly purified human neutrophils appears to be mainly mediated through the CD11b/CD18 integrin.

#### **A.2.3 CyaA-mediated cAMP increase and toxicity are specifically blocked by an anti-CD11b mAb**

[0124] To evaluate the physiological relevance of CD11b/CD18-dependent CyaA binding, we studied the effect of blocking mAbs on the cytotoxicity of CyaA. We first measured the amount of cAMP produced in J774A.1 cells exposed to CyaA in the presence of various mAbs. As shown in Figure 4a, the increase in the intracellular cAMP content induced by CyaA was totally abolished when cells were preincubated with the M1/70 anti-CD11b mAb. The C17/16 anti-murine CD18 mAb had that did not block CyaA cell binding (figure 2) had no effect on the intracellular cAMP content of CyaA treated cells. Thus, these data strongly suggest that the increase in intracellular cAMP induced by CyaA is dependent upon the interaction of the toxin with CD11b. To further analyze the requirement of this molecule for the toxicity of CyaA, we evaluated the effect of mAbs specific for the different chains of the  $\beta_2$  integrin family on CyaA mediated cell death. Figure 4b shows that anti-CD11b mAb J774A.1 dramatically reduced the cell death induced by CyaA (88 % inhibition). The cell death induced by CyaA was unaffected when J774A.1 were preincubated with mAbs that did not block toxin binding to cells (anti-CD11a, CD11c or CD18 or a control mAb). [0125] Taken together, these data indicate that CyaA binding through CD11b is strictly required for CyaA mediated toxicity in J774A.1 cells.

#### **A.2.4 Transfection of CHO cells with CD11b/CD18 confers sensitivity to CyaA**

[0126] To confirm the role of CD11b in CyaA binding, we used CHO cells transfected with the human integrins

CD11b/CD18 or CD11c/CD18 or mock transfected (vector alone). As shown in Figure 5a, CyaA could bind, at 37 °C, to these cell lines. However, CyaA binding was efficient and saturable in CHO cells expressing CD11b/CD18 but not in CD11c/CD18 or mock-transfected cells. The affinity of CyaA for CD11b/CD18 transfected cells was in the nM range ( $K_d = 0.7 \pm 0.09$  nM). At 4 °C, the efficiency of CyaA binding was reduced as compared with the binding at 37 °C (Figure 5b). At this temperature, the differences between CD11b/CD18 transfected cells and the two other cell lines were more pronounced. [0127] Since we found that CD11b was required for CyaA mediated toxicity in J774A.1, we then determined if CD11b expression was sufficient to confer a CyaA-sensitive phenotype to CHO transfected cells. In line with previous reports [Gordon et al, 1988], CyaA induced a notable amount of intracellular cAMP in CHO cells transfected with CD11c/CD18 or in control mock-transfected cells, but only at high concentrations of toxin (5 µg/ml, figure 5c). In contrast, CyaA increased intracellular level of cAMP in CD11b/CD18 transfected CHO cells even at the lowest concentration studied (0.05 µg/ml). Moreover, the cAMP production in response to 5 µg/ml CyaA was 4 to 5 times more elevated in CD11b/CD18 transfected cells, as compared to CD11c/CD18- or mock-transfected cells.

[0128] We also evaluated the role of CD11b/CD18 in CyaA-mediated cell death. As shown in figure 5d, more than 50% of CHO transfected with CD11b/CD18 were killed after 4 hours incubation with 5 µg/ml of CyaA, whereas CD11c/CD18- or mock-transfected cells were not affected by this treatment.

[0129] Altogether, these results thus clearly established that expression of human CD11b/CD18 integrin is sufficient to create a high affinity receptor for CyaA in CHO cells.

#### **A.3 Discussion: A receptor for CyaA**

[0130] Unlike other toxins, CyaA has been considered for a long time, as independent of any receptor binding. This is based on the observations that i) CyaA can intoxicate *in vitro* a wide variety of model cell lines from various origin [Ladant et al, 1999] ii) CyaA binds to Jurkat cells and sheep erythrocytes in a non saturable fashion [Gray, et al 1999]. In fact, these observations established that non-specific adsorption of CyaA to lipid membranes leads to some translocation of the catalytic domain into the cytosol. However, they did not rule out the existence of a specific receptor. We showed in this study on myeloid cell lines that the binding and the toxic properties of CyaA are dependent on its interaction with the integrin CD11b/CD18. Efficient and saturable binding correlates with the expression of CD11b and is fully and specifically blocked by anti-CD11b mAbs. Moreover, expression of CD11b/CD18 in CHO cells dramatically enhances the binding of CyaA, resulting in an increased sensitivity to intoxication by this toxin. Our re-

sults are the first evidence supporting the interaction of CyaA with a cell-surface molecule specifically expressed on leukocytes. The nearly complete blockade of CyaA binding by anti-CD11b mAbs suggests that CD11b is the main receptor for CyaA in the cell lines tested. The lack of efficient binding to CD11c/CD18 transfectants, or CD11a/CD18 expressing cells such as EL4 or LB27.4 suggest that CD11b/CD18 is the only integrin of the  $\beta_2$  family involved in the binding of CyaA to target cells.

[0131] In line with previous studies, we observed a detectable binding of CyaA to all cell lines tested. Furthermore, CyaA at high concentrations triggered a small but detectable cAMP increase in mock-transfected CHO cells, that is not associated to cell death. Thus, at high concentration, CyaA can bind and translocate to a wide variety of cell lines but efficient and saturable binding, translocation and killing is a hallmark of CD11b expressing cells.

[0132] Binding of CyaA to a member of the  $\beta_2$  integrin family is reminiscent of the behavior of other RTX toxins which were recently found to interact with these molecules [Lally et al, 1997; Li et al, 1999; Ambagala et al, 1999; Jeyaseelan et al, 2000]. The *E. coli* HlyA, that shares a strong homology with CyaA, forms cationic pores at the plasma membrane. HlyA exhibits a specificity for leukocytes but only at low concentration [Welch et al, 1991]. This relative specificity was shown to be mediated by its interaction with the integrin CD11a/CD18 [Lally et al, 1997]. Similarly, *A. actinomycetemcomitans* and *P. haemolytica* leukotoxin (LtxA and LktA, respectively), which are less promiscuous RTX toxins specific for human and bovine leukocytes, respectively, also interact with CD11a/CD18 [Lally et al, 1997; Li et al, 1999; Ambagala et al, 1999; Jeyaseelan et al, 2000]. Despite its strong homology with HlyA, CyaA recognizes another  $\beta_2$  integrin (CD11b/CD18) whose cellular distribution is different. Indeed, CD11b is expressed mostly on macrophages, neutrophils and dendritic cells, but not on the majority of T and B cells, whereas CD11a is expressed on all leukocytes including T and B lymphocytes.

[0133] This specific targeting of CyaA to CD11b expressing cells is exploited in the present invention to specifically target this particular subset of cells. Detoxified mutants of CyaA remaining invasive could be used for the delivery of pharmacologically active molecules to CD11b positive cells, without noticeably affecting other cell types.

## B. Targeted antigen delivery to the cytosol of myeloid dendritic cells and selective CTL priming

### B.1 Materials and Methods

#### B.1.1 Recombinant Adenylate Cyclase toxins and peptide

[0134] The pOVA synthetique peptide (SIINFEKL) originated from NEOSYSTEM and was diluted in PBS at 1mg/ml.

#### B.1.2 Immunization and assay for the detection of cytotoxic T cells

[0135] Female C57BL/6 (H-2<sup>b</sup>) from Iffa Credo (L'ar-bresle, France) were used between 6 and 8 weeks of age. TAP1 -/- (Van Kaer et al., 1992), CD4 -/- (Killeen et al., 1993), CD40 -/- (Kawabe et al, 1994) and B cell deficient  $\mu$ MT (Kitamura et al, 1991) bred onto a C57BL/6 background originated from the CDTA facility (CNRS, Orleans, France) and were bred in the Institut Pasteur facilities. Animals were intravenously immunized with Ag in PBS. Seven days post-injection, animals were sacrificed and the spleen was removed. Single cell suspensions of splenocytes ( $2.5 \times 10^7$  cells) were restimulated in 10 ml CM (see below) with irradiated spleen cells ( $2.5 \times 10^7$  cells) for 5 days in the presence of 1  $\mu$ g/ml pOVA. Cytotoxicity assay was performed exactly as previously described (Fayolle, et al., 1999).

#### B.1.3 Cell lines

[0136] B3Z (Karttunen et al., 1992), a CD8+ T cell hybridoma specific for the OVA 257-264 peptide (SIINFEKL) in the context of H-2K<sup>b</sup> was a generous gift from Dr N. Shastri (University of California, Berkeley, USA).

#### B.1.4 Antigen presentation assays

[0137] All antigen presentation assays were performed by coculture of APC with B3Z in 96 well culture microplates (0.2 ml final volume) in RPMI 1640 supplemented with 10 % Fetal Calf Serum, 100 U/ml penicillin, 100  $\mu$ g/ml streptomycin, 2 mM L-glutamine, and  $5 \times 10^{-5}$  M 2-mercaptoethanol (complete medium, CM). The stimulation of B3Z cells ( $10^5$  cells/well) was monitored by IL-2 release in the supernatants of 18-24 hours cultures in the presence of APC. IL-2 was measured in CTL assay as previously described (Guernonprez et al., 1999). In some experiments (see figure legends), B3Z stimulation was assessed using the NF-AT lacZ reporter assay. LacZ activity in cell lysates was assessed with the CPRG substrate as previously described (Karttunen et al., 1992). Two antigen presentation assays were performed : i) *In vitro* assay: APC originated from naive mice were cocultured ( $10^5$ /well) with B3Z in the presence of Ag at various concentrations. In some ex-

periments, APC were preincubated or not with mAbs at 10 µg/ml for 40 minutes at 4°C, then Ag was added to the cells in a 100 µl final volume in the continuous presence of the mAbs. After a 4 hours pulse, APC were washed twice and put in coculture with B3Z. Purified mAbs used were against CD11b (M1/70 ratIgG2b, κ) or isotype-matched control and originated from Pharmingen (San Diego, USA). ii) *Ex vivo* assay : APC originated from mice previously intravenously immunized with various Ags and were put in culture with B3Z in a 0.2 ml final volume at various numbers of APC per well.

### B.1.5 Antigen presenting cells and sortings

[0138] Total spleen cells (TSC), low density (LDF) and high density (HDF) fractions were prepared according to the protocole of Steinman modified by Vremec et al. (Vremec et al., 1992). Briefly, spleens were digested with collagenase for 40 minutes at 37°C and then dilacerated and prepared in the continuous presence of EDTA 5mM. Cells were centrifugated on a dense BSA solution. Supernatant and pellet cells were collected apart and termed low density and high density fractions. CD11c staining was performed at 4°C in PBS supplemented with 5% of Fetal Calf Serum and 2mM EDTA (PBS-FACS) with the hamster HL3 mAb coupled to phycoerythrin (PE), fluoresceine isothiocyanate (FITC) or biotinylated and then revealed by Streptavidine-PE. CD8α staining was performed with the 53-6.7 mAb coupled to PE. CD11b staining was performed with the M1/70 mAbs coupled to PE or FITC. CD54R staining was performed with the B220 mAb coupled to PE or biotinylated and revealed by streptavidine-PE. All mAbs originated from Pharmingen. After two washes, cells were sorted using a FACStar (Beckton Dickinson, Mountain View, USA). Cells were aseptically recovered in CM. Purity of the sorted cells was checked on an aliquot of the sorted cells analyzed on a FACScan apparatus (Beckton Dickinson, Mountain View, USA). Purity of the sorted cells was typically between 80 and 98%. In other experiments (as mentioned in figure legends), CD11c+ cells were sorted directly from spleen collagenase digests using the CD11c Micro Beads and the Magnetic Cell Sorting technology following the supplier protocole (MACS, MiltenyiBiotec, Bergish Gladbach, Germany). Purity of the sorted cells ranged around 80% with this technique.

## B.2 Results

### B.2.1 CD4- and CD40- independent CTL priming after systemic immunization with CyaAOVA in the absence of adjuvant

[0139] The chicken ovalbumin, H-2K<sup>b</sup> restricted, SI-INFEKL epitope was used as an experimental model epitope. It was genetically inserted in the catalytic domain of a detoxified, still invasive mutant CyaA. C57BL/

6 (H-2<sup>b</sup>) mice were immunized iv once with 50 µg of the recombinant toxin or control saline solution. Seven days after immunization, CTL activity specific for pOVA was detected within splenocytes of CyaAOVA-immunized C57BL/6 mice but not in mice injected with saline or a control CyaA (figure 6a). Similar results were obtained with CD4 or CD40 deficient mice indicating that, unlike many other CTL responses (as those raised against cross-priming Ag (Bennett et al, 1997; 1998; Schoenberger et al., 1998, Ridge et al., 1998) CD4<sup>+</sup> T cell help was not mandatory for priming of CTL responses by CyaAOVA (figure 6b, c). Furthermore, B cells were not required since CTL responses were also obtained in B cell deficient mice (IgM<sup>-/-</sup>, figure 6d). Contaminant LPS, possibly acting as adjuvants, are not involved in the stimulation of CTL responses CyaAOVA since C57BL10ScSn and the LPS-hyporesponsive mice C57BL10ScCr displayed similar OVA-specific CTL response after CyaAOVA injection (not shown).

### B.2.2 In vitro and in vivo targeting of CyaAOVA presentation to CD11b-expressing cells

[0140] In order to better understand the immunogenicity of CyaAOVA, we intended to determine the APC involved in its presentation to CD8<sup>+</sup> T cells. Using the IL-2 secretion as a readout for stimulation, we show that B3Z, an H-2K<sup>b</sup>-restricted, anti-OVA CD8<sup>+</sup> T cell hybridoma, is stimulated *in vitro* by bulk splenocytes in the presence of CyaAOVA but not CyaALCMV (figure 7a). We intended to analyze the APC ability of three well defined splenic APC: DC (CD11c<sup>+</sup>), B cells (CD45R<sup>+</sup>) and macrophages/granulocytes (CD11b<sup>high</sup>+CD11c<sup>-</sup>). Due to the low percentage of CD11c<sup>+</sup> in total splenocytes (<1%), we performed density fractionation and sorted the CD11c<sup>+</sup> from the DC-enriched (4-10%) low density population by flow cytometry. The high density fraction contained only trace amounts of CD11c<sup>+</sup> cells. In contrast, the distribution of CD45R<sup>+</sup> and CD11b<sup>high</sup>+CD11c<sup>-</sup> (composed of granulocytes/macrophages) cells in both fractions allowed sortings on the total population for these markers. As shown in figure 7c, CyaAOVA was presented most efficiently by DC, less efficiently by CD11b<sup>high</sup>+CD11c<sup>-</sup> and B cells. This correlates with a quasi exclusive distribution of antigen presenting ability within the low density fraction of splenocytes (figure 7a). In sharp contrast, both high and low density fractions were able to stimulate B3Z in response to pOVA (not shown).

To detect K<sup>b</sup>-OVA complexes formed *in vivo* after immunization, the APC prepared from mice iv immunized 8-15 hrs before with 50 µg CyaAOVA were cocultured with B3Z *in vitro* without Ag addition (*ex vivo* assay). As for *in vitro* assays, APC responsible for CyaAOVA presentation were present exclusively in the DC-enriched low density fraction of splenocytes (figure 7b). The specificity of the assay was checked with APC from CyaALCMV-immunized mice that did not stimulated B3Z (fig-

ure 7b). In order to further characterize the low density APC involved in CyaAOVA presentation, we performed cell sortings: results shown in figure 7d show that DC (CD11c<sup>+</sup>) fraction was the more efficient APC. The macrophage/granulocyte (CD11b<sup>high</sup>\*CD11c<sup>-</sup>) and the B cells (CD45R<sup>+</sup>) sorted from the same fraction were very inefficient for the stimulation of B3Z.

To further characterize APC involved in CyaAOVA, we performed subfractionation of the splenic low density CD11c<sup>+</sup> DC in CD11c<sup>+</sup>CD8 $\alpha$ <sup>-</sup> myeloid subset and CD11c<sup>+</sup>CD8  $\alpha$ <sup>+</sup> lymphoid subset. *In vitro* and *ex vivo* assays (figure 7e and f, respectively) showed that antigen presenting ability for CyaAOVA was retained by the myeloid subset that also expressed CD11b<sup>+</sup>, unlike the lymphoid subset expressing low levels of this integrin (Pulendran *et al.*, 1997; Vremec *et al.*, 1997). The inability of the CD11c<sup>+</sup>CD8  $\alpha$ <sup>+</sup> lymphoid subset to present CyaAOVA was specific for CyaAOVA since CD11c<sup>+</sup>CD8 $\alpha$ <sup>+</sup> and CD11c<sup>+</sup>CD8 $\alpha$ <sup>-</sup> presented equally well the pOVA synthetic peptide to B3Z.

*In vitro* and *ex vivo* assays performed with splenocytes from control (C57BL/6) or B cell-deficient mice (IgM<sup>-/-</sup>) confirmed the poor contribution of B cells to CyaAOVA presentation *in vitro* and *in vivo* (figure 7g and h). In line with these results, CTL responses induced by CyaAOVA were not significantly affected in B cell-deficient mice as compared to control mice (figure 5d).

### **B.2.3 MHC I-restricted presentation of CyaAOVA by dendritic cells depends on the cytosolic delivery of the recombinant toxin both *in vitro* and *in vivo***

[0141] To determine whether CyaAOVA presentation depends on the cytosolic delivery of the OVA epitope or extracellular loading, we performed Ag presentation assays with total splenocytes or CD11c<sup>+</sup> DC from TAP<sup>-/-</sup> or control TAP<sup>+/+</sup> splenic purified from naive animals (*in vitro*, figure 8a) or from animals immunized iv with CyaAOVA (*ex vivo*, figure 8b). Results show that CyaAOVA presentation by dendritic cells is fully dependent on TAP either *in vitro* or *in vivo*. Since pOVA presentation is a TAP-independent phenomenon, we checked the functionality of TAP<sup>-/-</sup> DC sorted from CyaAOVA-immunized mice by stimulating B3Z with these cells loaded *in vitro* with the pOVA peptide (not shown). These results show that *in vivo* presentation of CyaAOVA depends on its cytosolic delivery.

### **B.2.4 Interaction of CyaA with CD11b is required for cell binding and delivery of the inserted antigen to the cytosolic pathway for antigen presentation by MHC I**

[0142] We showed on part A that saturable and efficient binding of CyaA WT to CD11b<sup>+</sup> cells can be blocked specifically by anti-CD11b mAbs. Moreover, CD11b transfection specifically conferred saturable binding and sensitivity to CyaA WT to otherwise CD11b<sup>-</sup> cells

resistant to CyaA WT. Cell binding blockade by anti-CD11b mAbs inhibited subsequent intracellular delivery of the catalytic adenylate cyclase domain, cAMP elevation and cell death induced by CyaA WT. Since this results have been obtained on cell lines, it remained to determine if CyaA binds to splenocytes. We set up a flow cytometric assay to detect the fixation of a biotinylated, detoxified form of CyaA carrying the OVA peptide (CyaAOVAbiotine) to total splenocyte suspensions with streptavidin coupled to phycoerythrin. Using this assay, we observed that CyaAOVA binds to a subset of leukocytes within the total splenocyte suspension (5-7%). Preincubation with the anti-CD11b M1/70 mAb but not a control mAb abrogated this binding (figure 9a).

Furthermore, there is a correlation between the expression of CD11b and CyaAOVA binding to low density cells: CyaAOVA binds efficiently to CD11c<sup>+</sup>CD8 $\alpha$ <sup>-</sup> that expresses high levels of CD11b, less efficiently to CD11c<sup>+</sup>CD8  $\alpha$ <sup>+</sup> that expresses low levels of CD11b and very weakly to CD11c<sup>-</sup>CD8 $\alpha$ <sup>+</sup> T cells that do not express CD11b (figure 9b). It is noticeable that CyaOVA binds efficiently to a low percentage of CD11c<sup>-</sup>CD8 $\alpha$ <sup>-</sup> cells in correlation with the presence of CD11b<sup>high</sup><sup>+</sup> into this CD11c<sup>-</sup> population. Thus, CyaOVA biotine binding is mediated by CD11b (as for CyaA WT) and predicts the ability of a given cell type to present CyaOVA.

*In vitro*, we showed that the anti-CD11b mAb M1/70 blocks the CyaAOVA presentation by TSC cells to B3Z (figure 10a). This blockade is specific since i) a control mAb or mAbs specific for other  $\beta 2$  integrin family members (anti-CD11a, CD11c) had little or no effect (figure 10a and data not shown) ii) the presentation of pOVA was not affected by the anti-CD11b or none of these mAbs (figure 10b and data not shown). This confirms that CD11b is the main receptor for CyaAOVA at least in the spleen, and that CyaAOVA-CD11b interaction is mandatory for the presentation of the inserted epitope. Finally, to ascertain the role of CD11b expressing cells in CyaAOVA presentation, we performed sorting experiments on whole splenocyte cells from mice immunized with CyaAOVA or pOVA. Total splenocyte cells were sorted in CD11b<sup>+</sup> and CD11b<sup>-</sup> fractions. Whereas the two subpopulations stimulated B3Z after pOVA iv immunization (figure 10d), only the CD11b<sup>+</sup> subpopulation stimulated B3Z after CyaAOVA iv immunization (figure 10c).

Taken together, these results clearly establish that the presentation of the OVA peptide from CyaOVA is dependent on cell binding and thus on interaction with CD11b.

## **B.3 Discussion**

[0143] In the present study, using the detoxified adenylate cyclase of *Bordetella pertussis* as an epitope-delivery vector, we established a strategy for immunization that primes CTL responses after a single injection, bypassing the need for adjuvant requirement. We identi-

fied mechanisms that contribute to the high efficiency of detoxified CyaA as a vector:

### **B.3.1 CyaA target myeloid dendritic cells through its interaction with the CD11b integrin**

[0144] Antigen presenting assay to a specific CD8<sup>+</sup> T cell hybridoma using *in vitro*- or *in vivo*-loaded APC (*in vitro* and *ex vivo* assay, respectively) demonstrated that the most efficient APC for CyaAOVA are CD11c<sup>+</sup> DC. Indeed, all the Ag presenting ability for CyaAOVA belonged to the low density fraction of splenocytes that retains DC. Cell sorting of defined cell types revealed that CD11c<sup>+</sup> DC cells are much more efficient than CD11c<sup>+</sup>CD11b<sup>high</sup> cells. The minor contribution observed for B cells (CD45R<sup>+</sup>) was confirmed by efficient presentation of CyaAOVA (*in vitro* and *ex vivo*) and CTL responses in B cell-deficient mice.

### **B.3.2 CyaA delivers Ag to the cytosolic pathway for MHC class I presentation *in vivo***

[0145] Here we show the dependence of CyaOVA presentation to total splenocytes *in vitro*. Strikingly, we also show that *in vivo* presentation of CyaAOVA takes also place according a TAP-dependent pathway. This lead to the conclusion that CyaAOVA presentation *in vivo* resulted effectively from cytosolic delivery and not from an eventual extracellular degradation.

### **B.3.3 CTL priming bypass CD4<sup>+</sup> T cell help and is independent on CD40 signaling**

[0146] Maturation from an immature stage toward a mature stage is characterized by i) a decrease in Ag capture ability, ii) an increase in T cell priming ability, iii) a migration from Ag sampling sites (marginal zone in the spleen) toward T cell area (peri arteriolar sheets in the spleen) where they maximize the probability of encounter with Ag-specific T cells (De smedt *et al.*, 1996). In addition to Ag presentation by DC, the maturation phase is now widely assumed as a prerequisite for T cell priming. *In vitro* studies have highlighted the role of CD4<sup>+</sup> T cells in signalling DC maturation, notably via CD40L-CD40 interaction (Bell *et al.*, 1999). In the case of CD8<sup>+</sup> T cells priming after the crosspriming of cellular Ag, CD4<sup>+</sup> T cells dispensate their help to CD8<sup>+</sup> T cells in a CD40-dependent mechanism (Schuurhuis *et al.*, 2000; Bennett *et al.*, 1998; Schoenberger *et al.*, 1998; Ridge *et al.*, 1998). Since CyaAOVA primes CTL in a CD4 and CD40 independent way, it is tempting to speculate that detoxified CyaA could be endowed of intrinsic adjuvanticity.

### **B.3.4 Conclusion**

[0147] The present study represents the first characterization, to our knowledge, of a proteinaceous vaccine vector that fits both targeting to professional APC, cy-

tosolic delivery of the vectorized Ag and adjuvant-free CTL priming. Moreover, we elucidated the mechanism of cell targeting by demonstrating that Ag presentation is dependent on the interaction between CyaA and CD11b, its receptor. Hence, the cellular specificity of CyaA is serendipitously adapted to the Ag delivery purpose. Finally, the cellular specificity of CyaA or other bacterial toxins may serve the cytosolic delivery of a wide set of pharmaceutically-relevant molecules whose effects should be targeted on a restricted set of cells.

## **BIBLIOGRAPHY**

### **[0148]**

1. Aichele, P., D. Kyburz, P.S. Ohashi, B. Odermatt, R.M. Zinkernagel, H. Hengartner, and H. Pircher. 1994. Peptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model. *Proceedings of the National Academy of Sciences of the United States of America* 91, no. 2:444-8.
2. Aichele, P., K. Brduscha-Riem, R.M. Zinkernagel, H. Hengartner, and H. Pircher. 1995. T cell priming versus T cell tolerance induced by synthetic peptides. *Journal of Experimental Medicine* 182, no. 1: 261-6.
3. Ballard, J.D., R.J. Collier, and M.N. Stambach. 1996. Anthrax toxin-mediated delivery of a cytotoxic T-cell epitope *in vivo*. *Proceedings of the National Academy of Sciences of the United States of America* 93, no. 22:12531-4.
4. Bassinet, L., P. Gueirard, B. Maitre, B. Housset, P. Gounon, and N. Guiso. 2000. Role of adhesins and toxins in invasion of human tracheal epithelial cells by *Bordetella pertussis*. *Infect Immun* 68, no. 4:1934-41.
5. Bell, D., J.W. Young, and J. Banchemereau. 1999. Dendritic cells. *Advances in Immunology* 72: 255-324.
6. Bennett, S.R., F.R. Carbone, F. Karamalis, J.F. Miller, and W.R. Heath. 1997. Induction of a CD8<sup>+</sup> cytotoxic T lymphocyte response by cross-priming requires cognate CD4<sup>+</sup> T cell help. *Journal of Experimental Medicine* 186, no. 1:65-70.
7. Bennett, S.R., F.R. Carbone, T. Toy, J.F. Miller, and W.R. Heath. 1998. B cells directly tolerize CD8 (+) T cells. *Journal of Experimental Medicine* 188, no. 11:1977-83.
8. Bennett, S.R., F.R. Carbone, F. Karamalis, R.A. Flavell, J.F. Miller, and W.R. Heath. 1998. Help for cytotoxic-T-cell responses is mediated by CD40

signalling [see comments]. *Nature* 393, no. 6684: 478-80.

9. Benz, R., E. Maier, D. Ladant, A. Ullmann, and P. Sebo. 1994. Adenylate cyclase toxin (CyaA) of *Bordetella pertussis*. Evidence for the formation of small ion-permeable channels and comparison with HlyA of *Escherichia coli*. *Journal of Biological Chemistry* 269, no. 44:27231-9.

10. Carbonetti, N.H., T.J. Irish, C.H. Chen, C.B. O'Connell, G.A. Hadley, U. McNamara, R.G. Tuskan, and G.K. Lewis. 1999. Intracellular delivery of a cytolytic T-lymphocyte epitope peptide by pertussis toxin to major histocompatibility complex class I without involvement of the cytosolic class I antigen processing pathway. *Infection & Immunity* 67, no. 2:602-7.

11. Casares, S., K. Inaba, T.D. Brumeanu, R.M. Steinman, and C.A. Bona. 1997. Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II-restricted viral epitope. *Journal of Experimental Medicine* 186, no. 9:1481-6.

12. Condon, C., S.C. Watkins, C.M. Celluzzi, K. Thompson, and L.D. Falo, Jr. 1996. DNA-based immunization by in vivo transfection of dendritic cells. *Nature Medicine* 2, no. 10:1122-8.

13. Confer, D.L., and J.W. Eaton. 1982. Phagocyte impotence caused by an invasive bacterial adenylate cyclase. *Science* 217, no. 4563:948-50.

14. Coote, J.G. 1992. Structural and functional relationships among the RTX toxin determinants of gram-negative bacteria. *FEMS Microbiol Rev* 8, no. 2:137-61.

15. Crowley, M., K. Inaba, and R.M. Steinman. 1990. Dendritic cells are the principal cells in mouse spleen bearing immunogenic fragments of foreign proteins. *Journal of Experimental Medicine* 172, no. 1:383-6.

16. De Smedt, T., B. Pajak, E. Muraille, L. Lespagnard, E. Heinen, P. De Baetselier, J. Urbain, O. Leo, and M. Moser. 1996. Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. *Journal of Experimental Medicine* 184, no. 4: 1413-24.

17. Fayolle, C., D. Ladant, G. Karimova, A. Ullmann, and C. Leclerc. 1999. Therapy of murine tumors with recombinant *Bordetella pertussis* adenylate cyclase carrying a cytotoxic T cell epitope. *Journal of Immunology* 162, no. 7:4157-62.

18. Friedman, R.L., R.L. Fiederlein, L. Glasser, and J.N. Galgiani. 1987. *Bordetella pertussis* adenylate cyclase: effects of affinity-purified adenylate cyclase on human polymorphonuclear leukocyte functions. *Infection & Immunity* 55, no. 1:135-40.

19. Fuchs, E.J., and P. Matzinger. 1992. B cells turn off virgin but not memory T cells. *Science* 258, no. 5085:1156-9.

20. Gray, M., G. Szabo, A.S. Otero, L. Gray, and E. Hewlett. 1998. Distinct mechanisms for K<sup>+</sup> efflux, intoxication, and hemolysis by *Bordetella pertussis* AC toxin. *Journal of Biological Chemistry* 273, no. 29:18260-7.

21. Gross, M.K., D.C. Au, A.L. Smith, and D.R. Storm. 1992. Targeted mutations that ablate either the adenylate cyclase or hemolysin function of the bifunctional cyaA toxin of *Bordetella pertussis* abolish virulence. *Proceedings of the National Academy of Sciences of the United States of America* 89, no. 11:4898-902.

22. Gueirard, P., A. Druilhe, M. Pretolani, and N. Guiso. 1998. Role of adenylate cyclase-hemolysin in alveolar macrophage apoptosis during *Bordetella pertussis* infection in vivo. *Infection & Immunity* 66, no. 4:1718-25.

23. Guernonprez, P., D. Ladant, G. Karimova, A. Ullmann, and C. Leclerc. 1999. Direct delivery of the *Bordetella pertussis* adenylate cyclase toxin to the MHC class I antigen presentation pathway. *Journal of Immunology* 162, no. 4:1910-6.

24. Guery, J.C., F. Ria, and L. Adorini. 1996. Dendritic cells but not B cells present antigenic complexes to class II-restricted T cells after administration of protein in adjuvant. *Journal of Experimental Medicine* 183, no. 3:751-7.

25. Guery, J.C., F. Ria, F. Galbiati, S. Smirardo, and L. Adorini. 1997. The mode of protein antigen administration determines preferential presentation of peptide-class II complexes by lymph node dendritic or B cells. *International Immunology* 9, no. 1:9-15.

26. Guiso, N., M. Rocancourt, M. Szatanik, and J. M. Alonso. 1989. *Bordetella* adenylate cyclase is a virulence associated factor and an immunoprotective antigen. *Microbial Pathogenesis* 7, no. 5: 373-80.

27. Guiso, N., M. Szatanik, and M. Rocancourt. 1991. Protective activity of *Bordetella* adenylate cyclase-hemolysin against bacterial colonization. *Microbial Pathogenesis* 11, no. 6:423-31.

28. Harvill, E.T., P.A. Cotter, M.H. Yuk, and J.F. Miller. 1999. Probing the function of *Bordetella bronchiseptica* adenylate cyclase toxin by manipulating host immunity. *Infection & Immunity* 67, no. 3: 1493-500. 5
29. Hewlett, E., and J. Wolff. 1976. Soluble adenylate cyclase from the culture medium of *Bordetella pertussis*: purification and characterization. *Journal of Bacteriology* 127, no. 2:890-8. 10
30. Jeyaseelan, S., S.L. Hsuan, M.S. Kannan, B. Walcheck, J.F. Wang, M.E. Kehrl, E.T. Lally, G.C. Sieck, and S.K. Maheswaran. 2000. Lymphocyte function-associated antigen 1 is a receptor for *Pasteurella haemolytica* leukotoxin in bovine leukocytes. *Infection & Immunity* 68, no. 1:72-9. 15
31. Karimova, G., C. Fayolle, S. Gmira, A. Ullmann, C. Leclerc, and D. Ladant. 1998. Charge-dependent translocation of *Bordetella pertussis* adenylate cyclase toxin into eukaryotic cells: implication for the in vivo delivery of CD8(+) T cell epitopes into antigen-presenting cells. *Proceedings of the National Academy of Sciences of the United States of America* 95, no. 21:12532-7. 20
32. Karttunen, J., S. Sanderson, and N. Shastri. 1992. Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. *Proceedings of the National Academy of Sciences of the United States of America* 89, no. 13:6020-4. 25
33. Kawabe, T., T. Naka, K. Yoshida, T. Tanaka, H. Fujiwara, S. Suematsu, N. Yoshida, T. Kishimoto, and H. Kikutani. 1994. The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. *Immunity* 1, no. 3:167-78. 30
34. Khelef, N., H. Sakamoto, and N. Guiso. 1992. Both adenylate cyclase and hemolytic activities are required by *Bordetella pertussis* to initiate infection. *Microbial Pathogenesis* 12, no. 3:227-35. 35
35. Khelef, N., A. Zychlinsky, and N. Guiso. 1993. *Bordetella pertussis* induces apoptosis in macrophages: role of adenylate cyclase-hemolysin. *Infection & Immunity* 61, no. 10:4064-71. 40
36. Khelef, N., and N. Guiso. 1995. Induction of macrophage apoptosis by *Bordetella pertussis* adenylate cyclase-hemolysin. *FEMS Microbiology Letters* 134, no. 1:27-32. 45
37. Khelef, N., C.M. Bachelet, B.B. Vargaftig, and N. Guiso. 1994. Characterization of murine lung inflammation after infection with parental *Bordetella pertussis* and mutants deficient in adhesins or toxins. *Infection & Immunity* 62, no. 7:2893-900. 50
38. Killeen, N., S. Sawada, and D.R. Littman. 1993. Regulated expression of human CD4 rescues helper T cell development in mice lacking expression of endogenous CD4. *EMBO Journal* 12, no. 4: 1547-53. 55
39. Kitamura, D., J. Roes, R. Kuhn, and K. Rajewsky. 1991. A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. *Nature* 350, no. 6317:423-6.
40. Kyburz, D., P. Aichele, D.E. Speiser, H. Hengartner, R.M. Zinkernagel, and H. Pircher. 1993. T cell immunity after a viral infection versus T cell tolerance induced by soluble viral peptides. *European Journal of Immunology* 23, no. 8:1956-62.
41. Ladant D., Glaser P. and A. Ullmann. 1992. Insertional mutagenesis of *Bordetella pertussis* Adenylate cyclase. *Journal of Biological Chemistry* (4), no. 267: 2244-2250.
42. Ladant, D., and A. Ullmann. 1999. *Bordetella pertussis* adenylate cyclase: a toxin with multiple talents. *Trends in Microbiology* 7, no. 4:172-6.
43. Njamkepo, E., F. Pinot, D. Francois, N. Guiso, B.S. Polla, and M. Bachelet. 2000. Adaptive responses of human monocytes infected by *Bordetella pertussis*: the role of adenylate cyclase hemolysin. *J Cell Physiol* 183, no. 1:91-9.
44. Otero, A.S., X.B. Yi, M.C. Gray, G. Szabo, and E.L. Hewlett. 1995. Membrane depolarization prevents cell invasion by *Bordetella pertussis* adenylate cyclase toxin. *Journal of Biological Chemistry* 270, no. 17:9695-9697.
44. Porgador, A., K.R. Irvine, A. Iwasaki, B.H. Barber, N.P. Restifo, and R.N. Germain. 1998. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. *Journal of Experimental Medicine* 188, no. 6:1075-82.
45. Pulendran, B., J. Lingappa, M.K. Kennedy, J. Smith, M. Teepe, A. Rudensky, C.R. Maliszewski, and E. Maraskovsky. 1997. Developmental pathways of dendritic cells in vivo: distinct function, phenotype, and localization of dendritic cell subsets in FLT3 ligand-treated mice. *Journal of Immunology* 159, no. 5:2222-31.
48. Reis e Sousa, C., and R.N. Germain. 1999.

Analysis of adjuvant function by direct visualization of antigen presentation in vivo: endotoxin promotes accumulation of antigen-bearing dendritic cells in the T cell areas of lymphoid tissue. *Journal of Immunology* 162, no. 11:6552-61.1

49. Ridge, J.P., F. Di Rosa, and P. Matzinger. 1998. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. *Nature* 393, no. 6684:474-8.

50. Rogel, A., and E. Hanski. 1992. Distinct steps in the penetration of adenylate cyclase toxin of *Bordetella pertussis* into sheep erythrocytes. *The Journal of Biological Chemistry* 267, no. 31: 22599-22605.

51. Rose, T., P. Sebo, J. Bellalou, and D. Ladant. 1995. Interaction of calcium with *Bordetella pertussis* adenylate cyclase toxin. Characterization of multiple calcium-binding sites and calcium-induced conformational changes. *Journal of Biological Chemistry* 270, no. 44:26370-6.

53. Sakamoto, H., J. Bellalou, P. Sebo, and D. Ladant. 1992. *Bordetella pertussis* adenylate cyclase toxin. Structural and functional independence of the catalytic and hemolytic activities. *Journal of Biological Chemistry* 267, no. 19:13598-602.

54. Schoenberger, S.P., R.E. Toes, E.I. van der Voort, R. Offringa, and C.J. Melief. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions [see comments]. *Nature* 393, no. 6684:480-3.

55. Schuurhuis, D.H., S. Laban, R.E. Toes, P. Ricciardi-Castagnoli, M.J. Kleijmeer, E.I. van Der Voort, D. Rea, R. Offringa, H.J. Geuze, C.J. Melief, and F. Ossendorp. 2000. Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli [In Process Citation]. *J Exp Med* 192, no. 1:145-50.

56. Sebo, P., Glaser, P., Sakamoto, H., and Ullmann, A. 1991. *Gene* 104, 19-24.

57. Viola, A., G. Iezzi, and A. Lanzavecchia. 1999. The role of dendritic cells in T cell priming: the importance of being professional. In *Dendritic cells*. T. L. Lotze and A.W. Thomson, editors. Academic Press, San Diego. 251-253.

58. Vremec, D., and K. Shortman. 1997. Dendritic cell subtypes in mouse lymphoid organs: cross-correlation of surface markers, changes with incubation, and differences among thymus, spleen, and

lymph nodes. *Journal of Immunology* 159, no. 2: 565-73.

59. Vremec, D., M. Zorbas, R. Scollay, D.J. Saunders, C.F. Ardavin, L. Wu, and K. Shortman. 1992. The surface phenotype of dendritic cells purified from mouse thymus and spleen: investigation of the CD8 expression by a subpopulation of dendritic cells. *Journal of Experimental Medicine* 176, no. 1: 47-58.

60. Weiss, A.A., E.L. Hewlett, G.A. Myers, and S. Falkow. 1984. Pertussis toxin and extracytoplasmic adenylate cyclase as virulence factors of *Bordetella pertussis*. *Journal of Infectious Diseases* 150, no. 2:219-22

61. Weiss, A.A., and M.S. Goodwin. 1989. Lethal infection by *Bordetella pertussis* mutants in the infant mouse model. *Infection & Immunity* 57, no. 12: 3757-64.

62. Wolff, J., G.H. Cook, A.R. Goldhammer, and S. A. Berkowitz. 1980. Calmodulin activates prokaryotic adenylate cyclase. *Proceedings of the National Academy of Sciences of the United States of America* 77, no. 7:3841-4.

64. Zhong, G., C.R. Sousa, and R.N. Germain. 1997. Antigen-unspecific B cells and lymphoid dendritic cells both show extensive surface expression of processed antigen-major histocompatibility complex class II complexes after soluble protein exposure in vivo or in vitro. *Journal of Experimental Medicine* 186, no. 5:673-82.

65. Zinkernagel, R.M., S. Ehl, P. Aichele, S. Oehen, T. Kundig, and H. Hengartner. 1997. Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. *Immunological Reviews* 156: 199-209.

65. WO 93/21324 (INSTITUT PASTEUR). Recombinant mutants for inducing specific immune response.

66. Betsou et al. *Infect. Immun.* 1993 Sept., 61(9) 3583-3589.


67. Betsou et al. *Infect. Immun.* 1995 Sept., 63(9) 3309-3315.

## Claims

1. Use of *Bordetella* species adenylcyclase in the manufacturing of a proteinaceous vector for target-

- ing a molecule of interest specifically to CD11b expressing cells.
2. Use of a recombinant *Bordetella* adenylcyclase wherein a *Bordetella* species adenylcyclase is modified by insertion of a peptide of interest or conjugated to a molecule of interest for the preparation of a composition for the targeting of said peptide or molecule to CD11b expressing cells.
  3. The use according to claim 2 wherein said recombinant *Bordetella* species adenylcyclase is a fragment of the native *Bordetella* adenylcyclase toxin, wherein said fragment is capable of binding the CD11B receptor.
  4. The use according to anyone of claims 1 to 3 wherein the targeting of said molecule or peptide of interest is effective *in vivo*.
  5. The use according to any one of claims 1 to 4 wherein the molecule or peptide of interest is specifically targeted and translocated in the cytosol of CD11b expressing cells.
  6. The use according to any one of claims 1 to 5 wherein said CD11b expressing cells are myeloid dendritic cells.
  7. The use according to any one of claims 1 to 5 wherein said CD11b expressing cells are neutrophils.
  8. The use according to any one of claims 1 to 7 wherein the adenylcyclase is a genetically modified *Bordetella* species adenylcyclase.
  9. The use according to claim 8 wherein the adenylcyclase is a non toxic form.
  10. The use according to any one of claims 1 to 9 wherein the adenylcyclase is from *Bordetella pertussis*.
  11. The use according to any one of claims 1 to 10 wherein the molecule of interest is selected in the group comprising: lipopeptides, polysaccharides, oligosaccharides, nucleic acids, lipids and chemicals.
  12. The use according to claim 11 wherein the molecule of interest is an antigen.
  13. The use according to claim 11 wherein the molecule of interest comprises an epitope.
  14. The use according to claim 12 wherein said antigen is selected from the group consisting of an intracellular bacterial cell antigen, a tumoral antigen, a ham-pignary cell antigen, a viral antigen, a fungus antigen or a parasite cell antigen.
  15. The use according to claim 13 wherein said antigen is selected from the group consisting of: a poliovirus antigen, an HIV virus antigen, an influenza virus antigen, a choriomeningitis virus, a tumor antigen.
  16. The use according to any one of claims 1 to 11 wherein the molecule of interest is a drug chemically or genetically coupled to the adenylcyclase toxin.
  17. The use according to claim 16 wherein the drug is an anti-inflammatory drug.
  18. An immunogenic composition formulated for intravenous administration in an animal or a human host characterized in that it comprises a recombinant *Bordetella* adenylcyclase which comprises an antigen inserted in the catalytic domain.
  19. A pharmaceutical composition for administration in a human or an animal formulated for targeting a molecule of interest specifically to CD11b expressing cells characterized in that said molecule of interest is coupled to a *Bordetella* species adenylcyclase.
  20. The immunogenic or pharmaceutical composition according to claim 18 or 19 wherein the adenylcyclase is a genetically modified adenylcyclase.
  21. The immunogenic or pharmaceutical composition according to claim 20 wherein the genetically modified adenylcyclase is able to translocate the molecule of interest specifically in the cytosol of CD11b expressing cells.
  22. The immunogenic or pharmaceutical composition according to claims 18 to 20 wherein said CD11b expressing cells are myeloid dendritic cells.
  23. The immunogenic or pharmaceutical composition according to any one of claims 18 to 22, wherein said CD11b expressing cells are neutrophils.
  24. The pharmaceutical or immunogenic composition according to claims 18 to 23, wherein the molecule of interest is selected in the group comprising: lipopeptides, polysaccharides, oligosaccharides, nucleic acids, lipids and chemicals.
  25. The pharmaceutical or immunogenic composition according to claims 18 to 24, wherein said composition comprises a nucleic acid construction encoding the recombinant *Bordetella* species adenylcyclase comprising a recombinant *Bordetella* spe-

- cies adenylate cyclase coupled to a molecule of interest.
26. The pharmaceutical or immunogenic composition according to claim 24, wherein the molecule of interest is a drug.
27. The pharmaceutical composition according to claim 26, wherein the drug is an anti-inflammatory drug.
28. The pharmaceutical or immunogenic composition according to claims 18 to 24, wherein the molecule of interest is an antigen.
29. The immunogenic or pharmaceutical composition according to claim 28 wherein the antigen is selected from the group consisting of: an intracellular bacterial cell antigen, a tumoral cell antigen, a viral antigen, a fungus antigen or a parasite cell antigen.
30. The immunogenic or pharmaceutical composition according to claim 29 wherein the antigen is selected from the group consisting of: a poliovirus antigen, an HIV virus, an influenza virus antigen, a choriomeningitis virus antigen, a tumor antigen.
31. The immunogenic or pharmaceutical composition according to any one of claims 18 to 30 wherein said composition is devoid of priming adjuvants.
32. Use of the immunogenic or pharmaceutical composition according to any one of claims 27 to 31 for the preparation of a vaccine or an immunotherapeutic composition.
33. A proteinaceous vector for delivery of a molecule of interest, specifically to CD11b expressing cells, characterized in that said vector comprises a *Bordetella* species adenylcyclase coupled to said molecule of interest.
34. The proteinaceous vector according to claim 33 wherein said vector is also able to deliver the molecule of interest specifically in the cytosol of CD11b expressing cells.
35. The proteinaceous vector according to claim 33 or 34 wherein said CD11b expressing cells are myeloid dendritic cells.
36. The proteinaceous vector according to claim 33 or 34 wherein said CD11b expressing cells are neutrophils.
37. The proteinaceous vector according to any one of claims 33 to 36 wherein the adenylcyclase is a genetically modified adenylcyclase.
38. The proteinaceous vector according to claim 37 wherein the adenylcyclase is a non toxic adenylcyclase.
39. The proteinaceous vector according to any one of claims 33 to 38 wherein the adenylcyclase is from *Bordetella pertussis*.
40. The proteinaceous vector according to claims 33 to 39, wherein said molecule of interest is selected in the group comprising: lipopeptides, polysaccharides, oligosaccharides, nucleic acids, lipids and chemicals.
41. The proteinaceous vector according to any one of claims 33 to 40, wherein said molecule of interest is a drug chemically or genetically coupled to said adenylcyclase.
42. The proteinaceous vector according to claim 41, wherein the molecule of interest is an epitope.










Figure 2




**Figure 3**



**Figure 4**




**Figure 5**



**Figure 6**

LA Syntverti 14/08 -legd:Layout-11 - Fri Aug 25 14:10:58 2000



# APC  
Figure 7





Figure 8

a



b





Figure 9



**Figure 10**



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 00 40 2562

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X, D	WO 93 21324 A (PASTEUR INSTITUT) 28 October 1993 (1993-10-28)  * page 6, paragraphs 2,3 * * page 11 - page 12, paragraph 1 * * page 16, paragraph 1 * * page 21, paragraph 1.6 - page 22 *	1-16, 18-26, 28-42	A61K39/385 A61K47/48 A61K39/00 A61P29/00 A61P31/00 A61P33/00 A61P35/00
X	FAYOLLE C. ET AL: "Therapy of murine tumors with recombinant Bordetella pertussis Adenylate Cyclase carrying a cytotoxic T cell epitope" THE JOURNAL OF IMMUNOLOGY, vol. 162, 1999, pages 4157-4162, XP002169918 * the whole document *	1-16, 18-26, 28-42	
X	GUERMONPREZ P. ET AL: "Direct delivery of the Bordetella pertussis adenylate cyclase toxin to the MHC class I antigen presentation pathway" THE JOURNAL OF IMMUNOLOGY, vol. 162, 1999, pages 1910-1916, XP002169919 * the whole document *	1-16, 18-26, 28-42	TECHNICAL FIELDS SEARCHED (Int.Cl.7)  A61K
X	DADAGLIO GILLES ET AL: "Induction of a polarized Th1 response by insertion of multiple copies of a viral T-cell epitope into adenylate cyclase of Bordetella pertussis." INFECTION AND IMMUNITY, vol. 68, no. 7, July 2000 (2000-07), pages 3867-3872, XP002169920 ISSN: 0019-9567 * the whole document *	1-16, 18-26, 28-42	
		-/--	
The present search report has been drawn up for all claims			
Place of search <b>THE HAGUE</b>		Date of completion of the search <b>19 June 2001</b>	Examiner <b>Fernandez y Branas, F</b>
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 03/82 (P04C01)



European Patent  
Office

## EUROPEAN SEARCH REPORT

Application Number  
EP 00 40 2562

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	LADANT DANIEL ET AL: "Bordetella pertussis adenylate cyclase: A toxin with multiple talents." TRENDS IN MICROBIOLOGY, vol. 7, no. 4, April 1999 (1999-04), pages 172-176, XP001009743 ISSN: 0966-842X * the whole document *	1-16, 18-26, 28-42	
T	GUERMONPREZ PIERRE ET AL: "The adenylate cyclase toxin of Bordetella pertussis binds to target cells via the alphaMbeta2 integrin (CD11b/CD18)." JOURNAL OF EXPERIMENTAL MEDICINE, vol. 193, no. 9, 7 May 2001 (2001-05-07), pages 1035-1044, XP002169921 ISSN: 0022-1007 * the whole document *	1-42	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
The present search report has been drawn up for all claims			
Place of search <b>THE HAGUE</b>		Date of completion of the search <b>19 June 2001</b>	Examiner <b>Fernandez y Branas, F</b>
<p><b>CATEGORY OF CITED DOCUMENTS</b></p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons &amp; : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03/82 (P04C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 40 2562

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

19-06-2001

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9321324 A	28-10-1993	CA 2133999 A	28-10-1993
		EP 0637335 A	08-02-1995
		US 5503829 A	02-04-1996
		US 5679784 A	21-10-1997
		US 5935580 A	10-08-1999
<hr/>			

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**